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LIQUID CHROMATOGRAPHY - MASS SPECTROMETRIC ANALYSIS OF CLINICALLY
AND PHARMACOLOGICALLY RELEVANT MOLECULES

RAGHAVI KAKARLA
ABSTRACT

Liquid Chromatography-Mass Spectrometry is an advanced analytical technique
that offers high sensitivity and specificity and has been increasingly used for analysis of a
wide variety of compounds including clinically and pharmacologically relevant molecules.

In this dissertation we describe qualitative and quantitative liquid chromatographic mass

spectrometric methods to analyze both small molecules and larger macromolecules that
provide useful insights into diagnosis and management of several diseases. An LC-

MS(/MS) analytical method includes extraction of analytes of interest from the matrix
followed by liquid chromatographic separation and mass spectrometric detection. Chapter

I describes pre-analytical workflows and sample pretreatment techniques and theories
underlying LC-MS and instrumentation that are relevant to this work. The first chapter also

describes the process of method development followed by validation guidelines for
quantitative bio-analytical assays. Chapter II describes a novel, rapid, and simple
quantitative mass spectrometric method for endogenous molecules in human bile that are
associated with Cholangiocarcinoma and Cholelithiasis. The method was designed and

validated to overcome problems suffered by conventional methods such as time-consuming
extraction steps, carryover and unavailability of blank bile by employing simple dilution,

flow injection and standard addition to matrix effects respectively. In Chapter III, a

quantitative LC-MS/MS method was developed and validated for the determination of an
antitumor drug in mouse brain to support an investigation to study the effectiveness of

v

intracerebral microdialysis as an alternative route of administration. This method describes
a two-step extraction process using Proteinase K and ethanol protein precipitation to

overcome the low recovery and high matrix effects faced by previously reported methods.
Chapter IV describes investigation of feasibility of employing a less commonly used

proteolytic enzyme, aspartic acid N endopeptidase, in the digestion of prothrombin for

qualitative LC-MS analysis. This study could be employed to study distribution of variants
of des-gamma-carboxy-prothrombin, a biomarker which is elevated in hepatocellular
carcinoma and vitamin K deficiency to further identify a more specific variant(s) as a

biomarker. Finally, this dissertation is concluded with recommendations for qualitative and
quantitative LC-MS research methodology based on the findings herein and future

directions implicated by the impact of this work.
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CHAPTER I
INTRODUCTION

1.1 General introduction and scope of research

Liquid Chromatography-Mass Spectrometry is a hyphenated analytical technique
that unites the separation power of liquid chromatography with the detection capability of

mass spectrometry. It not only enables analysis of analytes in liquid phase but also offers
high sensitivity and specificity and thus is being increasingly utilized for qualitative and

quantitative analyses of small and large molecules such as biomarkers and drugs in
biological matrices. Biomarkers are biological molecules that indicate the presence and

progress of a disease and are important tools that aid in detection, diagnosis and treatment

of diseases. LC-MS is regarded as the analytical gold standard for quantification of small

molecules in the clinical laboratory as it provides superior specificity compared to widely
employed techniques such as immunoassays and HPLC [1]. In addition to small molecule

biomarkers, protein biomarkers are also being studied extensively because in contrast to
gene-based biomarkers they provide more meaningful and clinically relevant information.

The changes that take place during and after protein expression such as altered expression,
post translational modifications, structure, function, interactions, etc. may stimulate or

1

effect underlying mechanisms of many diseases including cancer. Proteomics revolves

around identification and understanding these changes and many attempts are being made
to identify biomarkers based on expressed proteins [2]. Proteins are made up of amino acids

varying in number and sequence and hence differ in their molecular structures and
physiochemical properties which allows for their separation and identification. With the

emergence of mass spectrometry, LC-MS has advanced as a major analytical tool for
proteomics analyses owing to its sensitivity, selectivity, accuracy and throughput [3].

Pharmacological studies provide important information related to safety and

efficacy of drugs and hence play a significant role in drug development [4]. When a drug
is administered into the body, the physicochemical and biochemical properties of the drug

and biophysical properties of the body dictate the fate of the drug. As most drugs are
exogenous, they do not have an appropriate biodistribution profile in the body unlike

endogenous molecules. Thus, their distribution is mostly systemic and lacks selectivity
which leads to unwanted side effects and is especially the case with cytotoxic anticancer
drugs. In order to improve safety, various targeted delivery systems and alternate routes of

administration are being investigated as promising alternatives to maximize therapeutic

efficacy and minimize systemic toxicity [5]. In order to evaluate the potential of the

targeted drug delivery systems, their biodistribution needs to be evaluated using analytical
methods that provide accurate quantification. LC-MS/MS has become the most commonly
used technique for pharmacokinetic studies as it not only offers accurate quantification of
drug/metabolite based on molecular weight but also provides structural information
pertaining to metabolism of the drug [6].

2

In this dissertation we describe qualitative and quantitative liquid chromatographic

mass spectrometric methods to analyze small and large molecules that provide useful
insights into diagnosis and management of various diseases. In general, LC-MS(/MS)
analysis includes extraction of analyte of interest from the matrix followed by liquid

chromatographic separation and mass spectrometric detection. In this chapter, we provide
a brief background on LC-MS, various sample preparation techniques for small molecules
and proteins, underlying principles and instrumentation, overview of method development
and validation.
Chapter II describes a simple method for high throughput analysis of glycocholic

acid and unconjugated bilirubin in human bile. High levels of glycocholic acid and
unconjugated bilirubin in bile are found to be associated with Cholangiocarcinoma and

Cholelithiasis respectively. Because of the hydrophobic nature of these metabolites,
current methods require time-consuming extraction steps and are prone to column
carryover in order to separate these from interfering matrix components. Furthermore, it is

virtually impossible to prepare a blank bile matrix that does not contain these analytes.
Therefore, we employed a dilute-and-shoot flow-injection mass spectrometric method to

quantify glycocholic acid and unconjugated bilirubin in bile using standard addition.
Bioanalytical method validation has also been performed in accordance with FDA

guidelines using clinical samples.
Chapter III focuses on a sample preparation method for LC-MS/MS analysis of an

anticancer drug, Temozolomide in mouse brain. Brain tumor treatment is not as successful
as the treatment of other tumors due to the systemic toxicity that limits the amount of

3

Temozolomide administered orally or intravenously. A potential strategy to combat
systemic toxicity is targeted drug delivery through intracerebral microdialysis which needs

to be investigated in animal models using a good analytical method prior to human clinical

trials. Unfortunately, current methods that quantify Temozolomide in mouse brain suffer

from poor extraction methods that result in high matrix effects (220%) and low recovery
(63%) and are not reliable for analysis. Hence, we have developed a sample preparation
with two-step extraction process that improved recovery to 82% and reduced to matrix

effects within 15%.
In Chapter IV, we focus on evaluating the feasibility of digestion of a protein

prothrombin with an unconventional protease called Aspartic acid N endopeptidase for in

order to elucidate the distribution of variants of abnormal prothrombin in two different
disease states. Biosynthesis of prothrombin requires post translational carboxylation of ten

glutamic acid residues present in its Gla domain. However, in Vitamin K deficiency and
hepatocellular carcinoma, carboxylation is defective leading to elevated levels of variants

of abnormal prothrombin called Des-gamma-carboxy-prothrombin. Those variants that are
elevated in hepatocellular carcinoma are also elevated in Vitamin K deficiency and

therefore lead to false positive results as immunoassays cannot distinguish between them.
An investigation of distribution of variants of the protein in both conditions might lead to
the discovery of a specific biomarker for hepatocelluar carcinoma. This could be achieved

by digesting the protein to produce a peptide that contains all the ten glutamic acid residues
(modified or unmodified) and analyzing them using LC-MS. The main goal of this study

is to evaluate the feasibility of using Aspartic acid N endopeptidase to digest prothrombin.

We have optimized the proteolytic digestion of prothrombin and compared the digestion
4

efficiency of the enzyme to that of Trypsin because the latter is the most commonly used

in LC-MS proteomic workflows.
1.2.1 High Performance Liquid Chromatography

High performance liquid chromatography is a separation technique and has a wide variety

of applications including qualitative/quantitative analyses and chemical purification.

HPLC separates components in a sample based on their affinities towards mobile and

stationary phases. Reverse Phase HPLC is a commonly used mode of HPLC which
separates analytes by using a non-polar stationary phase and a polar mobile phase. Fig.1.1

shows the schematic diagram of a typical HPLC system. A solvent reservoir holds mobile
phase that comprises of a mixture of solvents (like methanol, water, acetonitrile, along with

a suitable buffer) and is degassed and pumped pulse-free into an analytical column at a
controlled flow rate. A specified volume of a sample is injected and carried by the mobile
phase into the column. The column consists of relatively hydrophobic particles which act
as stationary phase to retain compounds. As mobile phase passes through the column,
components in the sample are eluted at different times depending on their affinity towards

the stationary and mobile phases. The degree and time of separation is dictated by various
factors like pKa of the compound, pH, organic modifier of the mobile phase, flow rate,

chemical nature and particle size of the stationary phase. Ultra-High Pressure Liquid
Chromatography (UHPLC) is a recent development and superior version of HPLC that

operates at high pressures and utilizes a HPLC column packed with sub-2u sized particles.
UPLC provides improved resolution, speed of separation and is being increasingly used

for bioanalysis to separate proteins, peptides, metabolites, drugs etc.

5

waste

Figure 1. 1 Schematic diagram of a typical HPLC system [7]
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1.2.2 Mass Spectrometry
Mass spectrometry is a detection technique that generates gaseous ions and

separates analytes based on their mass to charge ratios (m/Z). It not only provides accurate

molecular weight information but also helps in structure elucidation of molecules. With its
highly specific and sensitive analytical capabilities, it has become a powerful tool for

bioanalysis. Liquid Chromatography Mass Spectrometry (LC-MS) is a hyphenated
technique that combines the separating power of liquid chromatography with the analytical

capabilities of mass spectrometry. The high selectivity offered by mass spectrometry
enables accurate quantitation even if all analytes are not chromatographically resolved.

This makes quantitation feasible even without the use of a chromatographic column to
separate the analyte and is termed flow-injection mass spectrometry (FI-MS). Chapter II

describes the use of FI-MS/MS for quantification of endogenous molecules in bile in
chapter II. The basic components of a mass spectrometer are ion source, mass analyzer and

a detector.
1.2.2.1 Ionization source

The incoming components from HPLC are in liquid state at atmospheric pressure and must

be converted into gaseous ions for analysis. To achieve this, various ion sources can be
used as interfaces between HPLC and MS such as electro spray ionization (ESI),

atmospheric pressure chemical ionization (APCI) and atmospheric pressure photo
ionization (APPI). Electrospray ionization (ESI) is the most commonly coupled ionization
source for the analysis of non-volatile biomolecules. ESI is a soft ionization technique and
is widely used owing to its ability to ionize small molecules as well as large molecules.

7

Electrospray ionization occurs by the formation of charged droplets followed by

desolvation finally leading to the production of gas phase ions. As illustrated in fig. 1.2, a
positive or negative electric field is applied at the spray needle tip which produces ions in

liquid state. Repulsive forces between the ions push them towards the surface increasing
the charge density even more. When repulsive forces become higher than the surface
tension of the droplets, they are ejaculated as a stream into the desolvation zone forming a

‘Taylor cone’ at the end of the spray needle. A heating gas causes the solvent to evaporate
thereby shrinking the droplet and increasing the charge density further. The droplet

becomes unstable with increasing charge density and finally breaks apart into smaller

stable droplets when the repulsive forces exceed ‘Raleigh limit’. Desolvation and fission

of droplets continue to occur till each droplet has a single ion. In case of large molecules
such as proteins or large peptides, ions may contain multiple charges which reduces the
m/Z to be within the measurable range, thus allowing the detection of large molecules. ESI

can be done both in positive mode in which mostly protonation occurs resulting in the
formation of [M+H]+ ions and in negative mode which results in de-protonation producing
[M-H+]- ions. Protonation and deprotonation can be facilitated by addition of a buffer

based on the chemical nature of the analyte.

8

Figure 1. 2 Mechanism of electrospray ionization [8]
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1.2.2.2 Mass analyzer
The ions generated in the source are separated in the mass analyzer according to

their mass to charge ratio (m/Z). There are different types of mass analyzers that vary in
mass range limit, speed of analysis, mass accuracy and resolution. In this dissertation, a
triple quadrupole mass analyzer (Q-TRAP) was used for qualitative and quantitative

analyses. Quadrupole mass analyzers consist of four parallel rods made of inert metal

arranged radially as shown in fig. 1.3. A set of fixed DC and alternating Rf potentials are
applied to the rods which create electric fields in which ions travel in helical trajectories.
Only those ions with certain mass to charge (m/Z) have stable trajectories and pass through

the quadrupoles to reach the detector, while other hit the quadrupoles and fail to reach the

detector. Thus, Rf voltage can be varied to separate ions according to their mass to charge
ratios (m/Z). Quadrupole analyzers are inexpensive, offer high sensitivity and specificity
but have limited mass range. A triple quadrupole mass spectrometer (QqQ) consists of

three quadrupoles in tandem as shown in fig 1.3 with first and last quadrupole functioning
as mass filters with a collison cell in between. The first quadrupole (Q1) filters ions of

specified m/Z which are fragmented in the collision cell (q2) in the presence of an inert gas
like nitrogen while the third quadrupole (Q3) scans selected fragment ions of certain m/Z.
This type of scan is called as multiple reaction monitoring (MRM) and is preferred method
for quantitation as it offers high specificity and sensitivity.
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Figure 1. 3 Schematic diagram of a quadrupole [9]
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Figure 1. 4 Multiple reaction monitoring in triple quadrupole [10]
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1.2.2.3 Detector
Ions passing through the mass analyzer are drawn into the detector. An electron

multiplier is one of the most commonly used detectors in mass spectrometers and functions
based on secondary electron emission from a series of dynodes. Each ion that strikes a
dynode ejects more electrons which in turn strike the next dynode thus creating an ‘electron

pulse’. The cumulative signal of electron pulses is displayed as total count of ions per

second.

1.2 Pre-analytical workflow for analysis of clinically relevant molecules

1.3.1 Biological sample pre-treatment
In bioanalysis, analytes are present in a variety of biological specimen that are

common such as plasma, serum and urine, less common such as bile, cerebrospinal fluid,
specialized such as stool, dried blood spots or very specialized like tissue and secretions.
Each specimen differs from one another in terms of chemical constitution and complexity

of the matrix. The components present along with the analyte(s) in a biological/clinical
sample are proteins, lipids, salts, and other endogenous compounds that can significantly

influence the analytical method [11]. They tend to co-elute with the analyte and compete
for limited space on droplet surface during electro spray ionization resulting in matrix
effects such as ion suppression or ion enhancement. Furthermore, they can also foul the

column, affecting analyte peak shape, produce ghost peaks and high levels of background
13

noise. Hence samples must be pretreated to isolate analyte as much as possible from the
matrix components prior to LC-MS analysis. Cleaner samples produce more robust results,

increased sensitivity and selectivity. This is achieved by one or a combination of different
sample pretreatment techniques depending on the chemical nature, concentration of
analyte, matrix in which analyte is present, stability of analyte, potential interferences,

specific challenges such as sensitivity, throughput and more. For small molecules, sample

pre-treatment is done by dilution, protein precipitation, liquid-liquid extraction and solid
phase extraction. The discussion has been limited to those techniques relevant to this

research, which include dilution, protein precipitation, and solid phase extraction.

1.3.1.1 Dilute and Shoot
Dilute-and-shoot is the simplest sample pre-treatment method in which a suitable

solvent is added to the sample followed by centrifugation. The supernatant is then subjected
to LC-MS/MS analysis. Dilution not only facilitates high throughput analyses in a clinical
laboratory setting, but also is reported to reduce matrix effects significantly by decreasing
the concentration of matrix components in the sample [12]. However, dilute-and-shoot

technique is only suitable for less complex samples such as bile, urine and saliva and in
which concentration of analyte is fairly high compared to those of matrix components and

can be quantified even after dilution.
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1.3.1.2 Protein precipitation

Protein precipitation is one of the common sample pretreatment methods for biological
specimen in which proteins are present in higher concentrations such as blood, serum,
tissue etc. Proteins can contaminate or block HPLC columns and cause significant matrix
effects if not removed. Addition of protein precipitating agents disrupts the hydration layer
surrounding individual proteins and causes them to aggregate as illustrated in fig. 1.5. The

sample is then centrifuged at high speeds so that aggregated proteins form a pellet at the

bottom which can be easily separated. Organic solvents such as methanol, ethanol and
acetonitrile are among the most commonly used organic solvents for protein precipitation.

They decrease the dielectric constant of the protein solution, which increases the
electrostatic interactions between proteins resulting in protein aggregation [13]. Strong

acids such as perchloric acid and trichloroacetic acid form insoluble salts with the amine
groups of the proteins and precipitate proteins [14]. Ammonium sulfate is also a widely

used protein precipitating agent at high concentrations of <0.15 M. Salt ions compete with
proteins for water molecules exposing hydrophobic regions of proteins that are less soluble

in water. This process is called ‘salting out’ [15]. Other protein removal agents include

metal ions such as Zinc sulfate and ultrafiltration. Protein precipitation is not only simple
and cost effective but is also reported to decrease phospholipids from serum and plasma
samples [11]. However, protein precipitation as such might not be sufficient enough to
minimize matrix effects and is combined with other sample pretreatment techniques to

achieve much more cleaner samples.
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Figure 1. 5 Mechanism of protein precipitation [16]
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1.3.1.3 Solid Phase Extraction
Solid-phase extraction has been proven to be a reliable and versatile method for the
selective extraction and enrichment of a variety of analytes in biological matrices. The

principle of solid phase extraction is same as that of liquid chromatography; analyte from
solution is purified by sorption onto a solid-phase cartridge containing stationary phase

made of silica, C18, C8, C4, phenyl, etc. followed by elution of the analyte with a solvent
appropriate for instrumental analysis. In this work, we have employed a ZipTip based solid
phase extraction for removing salts and other unwanted chemicals in the sample prior to

LC-MS analysis. ZipTip contains solid sorbent, typically made of C18 material embedded
in a pipette tip. SPE is performed stepwise as shown in fig. 1.6.

•

Conditioning: Sorbent is activated by wetting/ conditioning first with an organic

solvent followed by an aqueous buffer.
•

Loading: Sample is then loaded into the ziptip and the analyte along with other
interfering molecules bind to the sorbent.

•

Washing: A buffer solution (typically composed of water and a modifier) is used to

wash the sorbent to remove undesirable, co-retained interfering molecules, leaving

the analyte molecules bound to the sorbent.
•

Eluting: Finally, the analyte molecules are eluted from the sorbent with a solvent
of higher elution strength comprising of appropriate percent of organic solvent and
buffer.

SPE not only reduces matrix effects significantly but can also be used to concentrate the
analyte after extraction.
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peptides

Figure 1. 6 Solid phase extraction using ZipTip
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1.3.2 Enzymatic digestion for proteomic analysis (middle-down approach)
There are two fundamental LC-MS based approaches in proteomics that are used

to identify different variants of proteins. In top-down approach, intact proteins are ionized

and analyzed directly by using high-resolution mass spectrometers. However, top-down
analysis is challenging and is not a good choice for proteins larger than 50 kDa as the
dynamic range of instruments is limited, the resulting spectra from multiply charged ions

is much complex and requires expensive high-resolution instruments such as like FT-ICR,

hybrid ion trap FT-ICR, and hybrid ion trap-orbitrap or tribid quadrupole-orbitrap mass
analyzers [17]. In bottom-up proteomics (also known as shotgun proteomics), proteins are

cleaved into peptides less than 3 kDa, typically by Trypsin, separated by SDS PAGE and/or
by HPLC and subjected to MS analysis. This approach is robust, ensures high throughput
and is the most widely used approach as it is based on the analysis of peptides that produce

more simpler spectra than intact proteins. However, Trypsin produces peptides that are
sometimes too short and the sequence coverage might not be efficient which is not ideal

for investigating PTMs. Middle-down proteomics, a newly emerging approach involves

proteolysis using unconventional enzymes to produce longer peptides within 3-10 kDa

range and offer the advantages of both top-down and bottom-up approaches. Differences
in all the three workflows is illustrated in Fig 1.7. Middle-down proteomics permits better
sequence coverage and facilitates the identification of neighboring PTMs as longer

peptides are analyzed. The workflow of middle-down proteomics is similar to that of
bottom-up except that Trypsin is replaced by other proteolytic enzymes like Asp-N and

Glu-C that have fewer cleavage sites than Trypsin [18]. Efficient proteolysis of proteins
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Figure 1. 7 Various analytical workflows in proteomics
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Figure 1. 8 Denaturation, reduction and alkylation steps before performing digestion
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Figure 1. 9 Chemical reactions of reduction and alkylation at cysteine residues [19]
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into peptides is a key step in bottom-up and middle-down proteomic workflows.
Proteolysis is performed by using proteolytic enzymes or chemicals and is usually more
efficient when proteins are converted to polypeptides that are more accessible to enzymes

for digestion. This is achieved through a sequence of steps involving denaturation,
reduction and alkylation as illustrated in fig. 1.8. Proteins are first denatured by treating
with 6-8M urea, 6M guanidine hydrochloride or detergents which disrupt hydrophobic

interactions causing the protein to unfold. This is followed by reduction with 5-15 mM
dithiothreitol (DTT) or 5-50 mM tris(2-carboxyethyl) phosphine (TCEP) which reduce

disulfide linkages between cysteine residues that are retained after denaturation, to thiol
groups as shown in fig 1.9. Reformation of disulfide bonds is prevented by alkylation with

Iodoacetamide (IAA) which adds carbamidomethyl group as shown in fig 1.9. IAA is
added at a concentration of approximately three times to that of DTT. After alkylation, a
suitable buffer is added to reduce the concentration of denaturing agent and pH favorable

for the protease to have maximal activity to digest the protein. This is followed by addition

of protease at an optimal enzyme-to-protein ratio and incubated at 37 °C for 1-18 hours.

After sufficient time, digestion is stopped by acidifying the digest by the addition of formic
or trifluoroacetic acid, as lowering the pH will inactivate, or quench the enzyme. Resultant

peptides are then extracted and analyzed.

1.5 Method development
LC-MS method development is an iterative process in which some of the steps are
optimized further to achieve desired results. Method development requires the knowledge
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of composition of sample matrix, chemical properties of analyte, expected concentration

range of the analyte etc. Fig. 1.10 shows the general steps involved in method development.
In general, the first step is optimization of an MS/MS method to monitor MRM channels.

This is done by manually infusing the standard solution of analyte(s) and the IS separately

into the electrospray ionization source of the mass spectrometer. Depending on the

response of the mass spectrometer, a suitable polarity (positive or negative mode) is chosen
and source dependent parameters are optimized. The most abundant molecular ion is

chosen as precursor ion which is fragmented by optimizing the compound dependent
parameters such as collision energy. The most abundant or unique fragment is chosen as a

product ion for quantification whilst the second most abundant is chosen for evaluating

specificity of the method. Once the mass spectrometric parameters are optimized for
analytes and the IS, an LC method is developed. Typically, a C18 HPLC column is chosen

for most separations although other stationary phases such as phenyl, C8 and HILIC among

others etc. are also used, depending on the hydrophobicity of the analyte of interest. In one

of our projects we have flow-injected samples into the mass spectrometer without using a

HPLC column in order to prevent the highly hydrophobic analytes sticking to the column
which further leads to carry over. Chromatographic parameters such as mobile phase

composition, elution profile, flow rate, run time, column temperature etc. are optimized
until desired separation and peak shapes are obtained. Optimization of MS and LC

parameters is followed by development (and simplification when possible) of sample

preparation. Samples are pretreated by dilution, protein precipitation, liquid-liquid
extraction, solid phase extraction etc. Finally, the method is validated after it has been

optimized further to obtain desired sensitivity and specificity.
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Figure 1. 10 Flowchart of analytical method development and optimization
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1.5 Quantitative Method Validation
Once developed, bio-analytical methods are validated to ensure that the data is

reliable by addressing crucial concerns such as accuracy, precision, specificity, selectivity,
linearity (range in measurements that provide reliable data), sensitivity, effect of sample

collection, and storage on the data. The U.S. FDA recommends validation of bioanalytical
methods and provides detailed guidance with the aid of calibrators and quality controls and
defines reference limits for some of the parameters.

Calibrators or calibration standards are biological matrices to which a known
amount of analyte has been spiked and are used to plot calibration curves from which

concentrations of analytes in quality control samples and study samples are determined. A

set of calibrators consists of a blank or double blank (does not contain analyte or internal
standard) a zero calibrator or single blank (does not contain analyte but contains internal
standard) and six non-zero calibrators covering the quantitation range, lower and upper
limits. Quality control is a biological matrix with a known quantity of analyte that is used

to monitor the performance of a bioanalytical method. Three levels of quality controls such
as low-quality control (LQC), medium-quality control (MQC) and high-quality control

(HQC), are freshly prepared for evaluating various validation parameters.

1.5.1 Calibration curve

Linearity refers to the relationship between the instrument response and the

calibration standards within the intended quantitation range. A calibration range should be
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chosen based on the range expected in the study. The simplest model that describes the
concentration-response relationship, suitable weighing factor and regression equation must

be used. Accuracy and precision of calibrators should be determined using a minimum of
six non-zero calibrators, a zero calibrator and a blank. %RE and %CV of non-zero

calibrators should be ± 15% of the nominal concentration except LLOQ which can be ±
20% of the nominal concentration.

1.5.2 Specificity and Selectivity

The extent to which a method can evaluate the analyte in the biological matrix
without interferences from matrix components is defined as selectivity. Specificity is the

ability of the method to unambiguously evaluate the analyte in the presence of other
components such as impurities, degradation products, matrix components etc. Selectivity

is determined by analyzing blank samples of appropriate biological matrix from at least six

individual sources. Specificity is evaluated for interference by cross reacting molecules,
concomitant medications etc.

1.5.2 Carryover
Carryover is defined as the appearance of the analyte in a sample from the previous
sample. FDA recommends that carry over should be eliminated during the stage of method
development. It is usually determined by injecting a double blank after running the upper
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limit of quantification. The instrument response should be <20% of the LLOQ in the double

blank at the retention time of the analyte.

1.5.3 Sensitivity

Sensitivity, also called the lower limit of quantitation (LLOQ) is defined as the
lowest analyte concentration in the biological matrix that can be quantified with acceptable
accuracy and precision. FDA recommends that the analyte response at the LLOQ should

be five times greater than or equal to zero, referred to as the calibrator/single blank.
Accuracy and precision of the LLOQ should be ± 20% of nominal concentration

determined form five replicates on same day and five different days.

1.5.4 Accuracy and Precision
Accuracy is defined as the degree of closeness of determined value to the nominal
or true value under proposed conditions. Precision is defined as closeness of agreement

among a series of measurements obtained from multiple sampling of the same homogenous
sample under the proposed conditions. Accuracy and Precision are determined on the same
day (Intra-day) and five different days (Inter-day) by evaluating five sets of three QCs for
percentage relative error (%RE) and percent coefficient of variance (%CV). FDA

recommends that %RE should be ± 15% of nominal concentration and %CV ± 15% for
three QCs.

28

1.5.5 Recovery
Recovery is defined as the extraction efficiency of an analytical method reported as

% of known amount of an analyte carried through the sample extraction and processing
steps of the method. Recovery need not be 100% but should be optimized to ensure that

the recovery of analyte and IS should be consistent and reproducible. Absolute and relative

recoveries of analyte are assessed by comparing responses of analyte (absolute recovery)
and response ratios of analyte and IS (relative recovery) in extracted samples to those in
extracts of blank samples spiked with analyte and IS after extraction.

1.5.6 Matrix effect
Matrix effect is defined as the effect on the method caused by components in a

study sample other than the analyte. The components in the matrix when co-eluting with
the analyte, tend to compete with analyte molecules for ionization resulting in either ion

suppression or enhancement. Moreover, the matrix effects vary between samples, as matrix
composition in biological samples is varied, making the assay difficult to control for these

interferences. FDA recommends that bioanalytical methods using LC-MS/MS must be
assessed and accounted for matrix effects. The absolute matrix effect of analyte is

determined by comparing the response of analyte in extracted biological sample matrix
with that of analyte in neat solution. The relative matrix effect is determined by comparing

the response ratio of analyte and IS to that of analyte in extracted biological sample matrix
with the response ratio of analyte and IS analyte in neat solution.
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1.5.7 Stability
Stability is the measure of intactness of the analyte in the biological matrix under

proposed storage and use conditions relative to the starting material for given time
intervals. Stability studies are performed by comparing the responses of QCs against

freshly prepared samples in different conditions covering exposure in autosampler,

benchtop, freeze-thaw cycles in addition to stability of stock solution and long-term
stability. FDA recommends accuracy of ± 15% of nominal concentration at two QC levels.

1.6 Conclusion
The use of LC-MS for qualitative and quantitative analysis of clinically relevant

molecules and drugs has been rapidly increasing owing to the technique’s sensitivity and
selectivity. In this chapter, a brief background on analysis of small and large molecules,

theories and instrumentation of HPLC and mass spectrometry, pre-analytical workflows,

method development and quantitative method validation guidelines stated by the US FDA
has been discussed and the application of these area of analytical science are presented in
the coming chapters.
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CHAPTER II

DEVELOPMENT AND VALIDATION OF A DILUTE AND SHOOT FLOW
INJECTION TANDEM MASS SPECTROMETRY METHOD FOR THE

QUANTIFICATION OF GLYCOCHOLIC ACID AND UNCONJUGATED
BILIRUBIN IN HUMAN BILE

2.1. Introduction
2.1.1. Cholangiocarcinoma and Glycocholic acid
Cholangiocarcinoma (CCA) or bile duct cancer arises from the epithelial lining of

intra-hepatic and extra-hepatic bile ducts. CCA is one of the most aggressive forms of
malignancies and around 8000 Americans are diagnosed annually [1]-[3]. Early diagnosis

of CCA is challenging due to its late clinical presentation and difficulties in early detection.
Current diagnostic methods lack the ability to distinguish benign from malignant tumors.

For example, imaging techniques such as ultrasonography, computed tomography (CT),
and magnetic resonance imaging (MRI) reveal bile duct blockage, but they are
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inefficient in differentiating the blockage caused by benign scarring or a malignant tumor
[1].

Glycocholic acid (GCA) is a conjugated bile acid produced from cholic acid. A significant
increase in the concentration of GCA has been observed in the bile of patients with CCA,
compared with those with benign biliary tract diseases [2], [4]. Because bile and its

constituents are directly in contact with the biliary epithelium, it could be an ideal
biological fluid for detection of CCA [4].

2.1.2. Cholelithiasis and Unconjugated Bilirubin
Cholelithiasis or gall stone disease effects approximately 6% of men and 9% of
women in the United States and is the primary cause for hospital admissions related to

gastroenterology [5]. Gall stones are anomalous lumps precipitating from bile and are
classified into cholesterol gall stones (mostly comprised of cholesterol) and pigment gall

stones (comprised of calcium complexes of bilirubin). Though it is a benign condition,
cholelithiasis could be a risk factor for life threatening diseases like cardiovascular disease
and cancer [6]. Cholelithiasis is mostly asymptomatic and the existence of gallstones is

only revealed during an ultrasound.

Unconjugated bilirubin (UBL) is a toxic metabolite of heme and is usually excreted

in bile after conjugation in the liver. In healthy conditions, UBL is present in very low
proportions in bile. However, studies have established that deconjugation occurs in bile
catalyzed by bacterial enzymes or non-enzymatic hydrolysis resulting in the formation of
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more UBL [7],[8]. Higher proportion of UBL in bile is considered as a risk factor for
Cholelithiasis as UBL is found to act as a nidus for the formation of cholesterol gall stones
[9]. UBL has also been identified as a component of biliary sludge that precedes the

formation of pigment stones [10]-[12]. UBL in bile could be a potential biomarker of

Cholelithiasis that requires further investigation to evaluate its potential.

Nevertheless, bile was not until recently a preferred biological fluid for clinical
analysis because sampling of bile required surgery. Advances in imaging techniques like

endoscopic retrograde cholangiopancreatography (ERCP) now makes it possible to sample
bile without surgical intervention. A thorough literature survey revealed a TLC and a

HPLC method to determine Bilirubin and a LC-MS method to determine GCA in human
bile respectively [7], [13], [14]. HPLC and TLC methods lack the specificity and accuracy

offered by mass spectrometry methods. Although LC-MS has unparalleled sensitivity and
accuracy, it suffers from various obstacles due to highly hydrophobic nature of bile acids

and matrix components that complicate its quantification. First, current methods require
time-consuming extraction steps in order to separate GCA or UBL from interfering matrix

components. Furthermore, because analytes strongly bind to the C18 reverse phase
columns strongly, it is necessary to frequently wash the column vigorously, which is not

practical in a clinical setting. Finally, it is virtually impossible to create a blank bile matrix
that does not contain GCA and UBL.
To overcome these problems, we employed dilute-and-shoot flow-injection

MS/MS (for short, FI-MS/MS) to quantify GCA and UBL simultaneously in bile, for which
standard addition calibration is also utilized. The high concentrations of GCA and UBL in

bile allow dilution of bile by as much as 800,000 times to minimize matrix effects [12].
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Diluted sample is then injected directly into the ionization source without LC separation,
avoiding column contamination and the problem of carryover. Sample preparation and run

time are also substantially minimized by using a FI-MS/MS method, whilst maintaining
quantification accuracy and precision [15], [16]. Moreover, we utilized a standard-addition

method for calibration, which not only does not require a blank matrix that is virtually
impossible to obtain, but also minimizes matrix effects. In standard addition, solutions
containing different concentrations of analyte are directly added to aliquots of the sample

[17]. Thus, any change in signal intensity between the sample and the spiked samples will

only result from change in analyte concentration and hence matrix effects are minimized.
Bioanalytical method validation has been conducted in accordance with FDA guidelines

[18].

2.2. Experimental
2.2.1. Chemicals

Glycocholic acid (C26H43NO6) was purchased from Sigma Aldrich, (St. Louis, MO,
USA). Bilirubin (C33H35N4O6 99%) was purchased from Acros Organics (Geel, AN,
Beligium). Dehydrocholic acid (C24H34O5, >98%) was a reference standard purchased from

USP (Rockville, MD, USA). HPLC grade methanol and Dimethyl sulfoxide (DMSO) was

purchased from EMD Millipore Corporation (Billerica, MA, USA) and Alfa Aesar (Ward
Hill, MA, USA) respectively. Deionized water was obtained from Barnstead D3750 Nano

Pure water purification system by Thermo Scientific (Waltham, MA, USA). Bile samples

were obtained from four volunteers at Mississippi State University.
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2.2.2. Instrumentation
Quantification was performed by liquid chromatography coupled to a triple

quadrupole-tandem mass spectrometer. The Shimadzu HPLC unit (Columbia, MD, USA)
consisted of binary pumps (Nexera LC-30 AD), degasser (a DUG20A3R), autosampler
(SIL-30 AC), column oven (CTO-10AVP) and a controller (CBM 20A). The AB SCIEX

5500 QTRAP mass spectrometer (Toronto, Canada) was equipped with an electrospray

ionization probe, triple quadrupole and a syringe pump. The instrument operation,
acquisition and processing of data was performed using AB SCIEX Analyst software.

2.2.3. Flow Injection
Flow injection of GCA, UBL and IS was performed isocratically at 30°C with a

carrier solvent comprising of 90% methanol at a flow rate of 0.3 mL/min. It should be

noted that a LC column was not used for separation. A 10 uf volume of the sample from

the autosampler vials was injected into the system and data was acquired for a run time of

2.5 min per sample.

2.2.4. Tandem mass spectrometry
Mass spectrometric analysis was performed in negative electrospray ionization
(ESI-) mode. Source and compound dependent parameters were optimized and the

conditions were as follows: curtain gas: 30 psi; ion spray voltage: -4500V; ion spray
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temperature: 400°C; ion source gases: 1 and 2 to 20 psi; declustering potential: -110 V;
entrance potential: -14 V; collision energy: -53 eV (GCA), -40 eV (UBL), and -44 eV (IS)

and cell exit potential: -25 eV. Quantitation of GCA and UBL was achieved in multiple
reaction monitoring (MRM) mode. The selected precursor-product ion pairs for GCA, UBL

and IS were m/Z 464.1 ® 74, 583.6 ® 285.3 and 401.2 ® 249.1 respectively.

2.2.5. Preparation of stock and working solutions
Stock solutions of GCA and IS were prepared separately in appropriate volumes of

methanol and UBL in DMSO to obtain concentrations of 1mg/mL. All stock solutions were

stored at -20°C. The working standard solutions of GCA and UBL (2.5, 5, 10, 20, 30, and
40 ug/mL for calibrators and 6.3, 14.1, 32 for quality controls (QCs)) were prepared by
serial dilution in methanol. A working solution of IS (20 ug/mL) was prepared by diluting
the stock solution of IS with methanol.

2.2.6. Preparation of bile samples by dilution
Bile samples were thawed to room temperature and vortexed for 2 minutes. 2 uL
of each bile sample was diluted to 8mL with methanol, vortexed for 2 min and centrifuged
at 14000 rpm for 20 minutes. A pooled bile sample (mixture of 4 lots of human bile
samples) was also treated in a similar way to yield diluted pooled bile. The supernatants

obtained after centrifugation were used to prepare calibrators and quality controls as
described below.
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2.2.7. Preparation of calibrators for standard addition
Calibrators (12.5, 25, 50, 100, 150 and 200 ng/mL) were prepared by spiking each
working standard solution (2.5, 5, 10, 20, 30 and 40 ug/mL) with 5 uL of diluted pooled

human bile (prepared as mentioned above). A single blank was prepared without spiking

the diluted pool bile with working standard solution. To ensure that the analyte
concentration in the sample was within the linear range and not below the LLOQ, an ‘initial
spike’ of 5 uL of 5 ug/mL of GCA and UBL were spiked into all the calibrators. The

volume of the solutions was then made up with methanol, vortexed, centrifuged at 14000
rpm for 20 min and the supernatant was transferred to an autosampler vial for analysis.

2.2.8. Preparation of quality controls (QCs)
Quality controls (QCs) (31.3, 70.7 and 160 ng/mL) were prepared by spiking
working standard solutions of GCA and UBL (6.3, 14.1 and 32 ug/mL) with 5 uL of diluted

pooled human bile and treated the same way as calibrators.
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2.3. Results and Discussion

2.3.1. Method Development

2.3.1.1. Multiple Reaction Monitoring
Detection of GCA, UBL and IS was carried out using a triple quadrupole mass

spectrometer. Since both GCA, UBL and IS have carboxylic acid side chains, negative ion

mode was chosen for ionization. Multiple reaction monitoring (MRM) was utilized to
ensure specific quantification by reducing the interference of other molecules present in
the bile. Experimentally, the most abundant ion was selected as precursor ion which was

subjected to collision-induced dissociation (CID). CID produces fragment ions and the
most abundant fragment ion was chosen as product ion for quantification. The precursor
and product ions selected for this study are shown in fig 2.1. The peaks at 464.1 Da 401.2
and 583.3 Da represent precursor ions and the peaks at 74.0, 249.1 and 285.2 represent

product ions for GCA, IS and UBL respectively. Specifically, the transitions used in MRM

were 464.1 ® 74.0 for GCA, 401.2 ® 249.1 for IS and 583.3 ® 285.2 for UBL. To ensure
that only analytes and no other ions were quantified, we also monitored additional

transitions (qualifiers) of GCA (m/Z 464.1 ® 402.4) and (583.6 ® 241.2) UBL as for
increased confidence in identifying the target analytes.
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Figure 2. 1 The MS/MS spectra of and proposed fragmentation pattern of (A) GCA (B) IS
(C) UBL in negative electrospray ionization mode.
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2.3.1.2. Sample Preparation and Flow injection
Because GCA, UBL and IS are highly hydrophobic, they can bind to C18 materials
very strongly materials very strongly, resulting in carry over, which poses a problem when

a column is used for separation. Hence, we employed a flow injection strategy to avoid this
issue by eliminating the use of a column.

This was possible considering that the

concentrations of GCA and UBL in bile are very high, meaning that these analytes can still
be detected even after substantial dilution of bile, and most importantly, such simple
dilution may be sufficient enough to avoid matrix effects when the separation column is
not used. Clearly, another benefit of dilution is that no extraction method is needed to first

retrieve the analytes from bile before analysis. Hence, bile is substantially diluted and then

directly injected (without any sample preparation) into the mass spectrometer. A carrier

solvent comprising of 90% methanol carried the injected sample as a plug into ESI of mass
spectrometer at a flow rate of 0.3 mL/min. We found that our method was reproducible,

evidenced by the fact that the detection signals were consistently detected at the same time
window in every run. The typical flow injection detection signals of GCA, IS and UBL

were displayed in fig. 2.2.

2.3.1.3. Standard addition
To quantify GCA and UBL in bile using a traditional calibration curve method, a blank

bile matrix without the analytes is required. However, it is virtually impossible to obtain
such blank matrix, as charcoal stripping, currently used not only removes GCA and UBL

from bile, but also removes other matrix components. As a consequence, the actual
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Intensity, cps

Figure 2. 2 Extracted flow-injection chromatograms of GCA, IS and UBL (from top to
bottom) in MRM mode
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composition of matrix after charcoal stripping is altered, not reflecting the true
nature of the bile sample [19].Standard addition is the method of choice for quantitation
when an endogenous amount of analyte is “inherently” present in matrix [17], [20], [21].

In our method, we employed standard addition to generate the calibration curve, which was

constructed using bile samples spiked with standard GCA and UBL solutions by plotting
the peak area ratio of analytes to IS vs the concentration of analytes added. The absolute
value of the x-axis intercept corresponds to the concentration of the analytes in a bile
sample.

2.3.2. Method Validation
The method was validated for linearity, accuracy, precision, matrix effects, LLOQ
and carryover according to the FDA bioanalytical method guidelines.

2.3.2.1. Linearity of standard addition calibration curve
A linear relationship between the concentration of analytes and the peak area ratio (the
product ion intensities of GCA and UBL to product ion intensity of IS) was determined
using pooled and individual human bile lots by plotting standard addition calibration

curves. To evaluate linearity, five replicates of analyte spiked bile calibrators at 12.5, 25,

50, 100, 150, 200 ng/mL and single blank were analyzed. The chromatograms are displayed
in fig. 2.2. Standard addition-calibration curves were plotted for pooled human bile and
individual lots with peak area ratios vs concentration using weighing factor of 1/x. The
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Table 2. 1 Linearity data of calibrators in pooled bile samples (n=3)

Spiked
concentration GCA
(ng/mL)
Determined
concentration
(ng/mL)
12.04 ± 2.45
12.5
25
26.73 ± 5.26
50
50.95 ± 5.80
100
97.63 ± 4.08
150
133.17 ± 6.90
200
217.17 ±10.60

UBL
% RE % CV

-3.7
6.9
1.9
-2.4
-11.2
8.6

20.37
19.66
11.39
4.18
5.18
4.88

Determined
concentration
(ng/mL)
11.03 ± 2.93
21.87 ± 5.08
37.98 ± 0.85
106.25 ±9.04
150.17±10.69
224.67±29.54

% RE

% CV

-11.78
-12.53
-24.03
6.25
0.11
12.33

20.27
33.13
10.56
19.91
20.00
38.61

% RE (percent relative error) = [(determined concentration - spiked concentration)/(spiked
concentration)] x 100
% CV (percent coefficient of variation) = (standard deviation/mean) x 100
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A

B

Figure 2. 3 Standard-addition calibration plot of A) GCA and B) UBL in pooled human
bile from four lots. The x-axes intercepts correspond to the actual concentration of GCA
and UBL
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correlation coefficients of standard addition curves of GCA and UBL were found to be

0.9857 and 0.9821 respectively as shown in fig. 2.3. The accuracy and precision values

were tabulated in table 1.1. %RE was found to be within the limit (±20% for LLOQ and
±15% for remaining calibrators) for GCA and UBL for all of the calibrators except third
calibrator of UBL. The precision values of second calibrator of GCA and five calibrators

of UBL were above the limit (±20% for LLOQ and ±15% for remaining calibrators).

2.3.2.2. Accuracy and Precision
The accuracy of a method defines the closeness of mean test concentration determined by
the method to the actual concentration of the analyte and is expressed as percent relative
error (%RE). Precision of a method defines the closeness of individual concentrations of

analyte to one another and is expressed as percent coefficient of variation (%CV).
Accuracy and precision of our method were evaluated by analyzing five replicates of QCs

at 31.25, 70.71 and 160 ng/mL on the same day (intra-day) and in five separate days (inter

day). The data for intra-day and inter-day accuracy and precision were presented in Tables

2.2 and 2.3. Accuracy was expressed as % RE and precision was expressed as %CV. For
GCA, the intra-day accuracy was within -1.44 - 18.1 and % RE of inter-day was within

9.02-14.8. The intra-day precision of GCA was within 11.45-12.53 while % CV of inter
day for five replicates on five separate days was 6.50-11.60. The intra-day accuracy for

UBL was between 5.99 - 21.42 while inter-day accuracy was within 10.69-20.96. The
intra-day precision of UBL ranged from 13.18 - 23.78 and inter-day precision was within
10.68 - 24.04. The above data suggests that the method has reasonable accuracy and
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Table 2. 2 Intra-day accuracy and precision of GCA and UBL in pooled bile (n=5)

Spiked
concentration GCA
UBL
(ng/mL)
Determined
% RE % CV Determined
% RE % CV
concentration
concentration
± SD
± SD
(ng/mL)
(ng/mL)
31.25
33.08
±
6.56
5.86
12.53
24.89
± 8.26
21.42 13.18
LQC
MQC 70.71
83.51 ± 9.73
11.45 69.28 ±19.81
9.41
23.78
18.1
157.7 ±16.70 -1.44
12.34 149.62±42.61 5.99
22.15
HQC 160.00
Intra-day accuracy and precision were determined at three QC levels using five lots of
pooled bile on same day.
% RE (percent relative error) = [(determined concentration - spiked concentration)/(spiked
concentration)] x 100
% CV (percent coefficient of variation) = (standard deviation/mean) x 100
QC
Level
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Table 2. 3 Inter-day accuracy and precision of GCA and UBL in pooled bile (n=5)

Spiked
concentration GCA
UBL
(ng/mL)
Determined
% RE % CV Determined
% RE % CV
concentration
concentration
± SD
± SD
(ng/mL)
(ng/mL)
33.57 ± 6.2
14.80 9.02
24.43 ±14.95 21.96 10.68
LQC 31.25
MQC 70.71
11.60 69.41 ± 1.72 10.69 24.04
69.61± 31.28 9.52
141.8 ±18.38 12.03 6.50
142.50 ±7.22 10.93 20.38
HQC 160.00
Inter-day accuracy and precision were determined at three QC levels using five lots of
pooled bile on five different days.
% RE (percent relative error) = [(determined concentration - spiked)/(spiked)] x 100
% CV (percent coefficient of variation) = (standard deviation/mean) x 100
QC
Level
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precision as most of %RE and %CV values were within the 15% limit set by the FDA and

some values of UBL were slightly over the limit.

2.3.2.3. Matrix effect
The presence of other components in a biological sample can lead to matrix effects

(such as ion suppression or enhancement) and bile does contain high concentrations of
various other molecules. Hence, both absolute and relative matrix effects on our method

were determined by comparing the peak area ratios of five replicates of QCs in bile samples
and solvent. Absolute matrix effects were determined by comparing the peak areas of
analytes in diluted bile samples and in neat solutions at three QCs. Relative matrix effects

were determined by comparing the peak area ratios of GCA/IS and UBL/IS in diluted bile
samples and in neat solutions at three QCs. The data are presented in table 2.4. The absolute

and relative matrix effects were expressed as %ME. The absolute matrix effect of GCA
was within 91.65 - 98.99% while relative matrix effects was 87.35 - 94.78%. The absolute

and relative matrix effects of UBL were within 86.77 - 91.85% and 88.93 - 98.24%
respectively. The data suggest that the use of dilution and standard addition has held the

matrix effects on both the analytes within the 15% limit set by the FDA guidelines.
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Table 2. 4 Absolute and relative matrix effects of GCA and UBL in pooled bile (n=5)

UBL
GCA
Absolute
Relative
Absolute
Relative
matrix effect matrix effect matrix effect matrix effect ±
± SD
± SD
± SD
SD
31.25
98.99 ± 10.37 94.78 ± 9.45 91.85 ±11.90 92.13 ± 13.08
LQC
MQC 70.71
96.36 ± 5.32
87.35 ± 3.54 90.33 ± 9.33 98.24 ±17.30
91.65 ± 4.87
91.66 ± 7.90 86.77 ± 7.48 88.93 ± 24.73
HQC 160.0
Matrix effect was determined at three QC levels using five lots of pooled bile.
Absolute matrix effect= (mean peak area of analyte in diluted bile)/(mean peak area of
analyte in neat solution).
Relative matrix effect= (mean peak area of analyte/IS in diluted bile)/(mean peak area of
analyte/IS in neat solution).
QC
Level

Spiked
concentration
(ng/mL)
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2.3.2.4. Lower limit of quantification
In our method, the lower limit of quantification (LLOQ) was defined as the

concentration of GCA and UBL in the lowest calibrator (12.5 ng/mL) used to construct the

standard addition calibration curve. We have conducted a study to examine reproducibility
of quantitation at the LLOQ level of 12.5 ng/mL, which was achieved by quantifying GCA
and UBL in five replicates of pooled bile samples containing 12.5 ng/mL. It was found that
the % CV for GCA and UBL were less than 20%, suggesting that our method is sensitive

enough to reproducibly detect GCA and UBL at a concentration as low as 12.5 ng/mL. It
must be noted that no study was conducted to determine whether our method can detect
analytes at the level of less than 12.5 ng/mL.

2.3.2.5. Carry over
Carry over problem is often associated with the column-based method, where the
analyte from earlier analyzed samples can stick to the column, affecting analysis of the

samples that are analyzed thereafter. This is particularly problematic with bile that contains
high concentrations of various highly hydrophobic molecules including GCA and UBL.

Although our method does not use any column, we did conduct a study to examine whether

any bile molecules including GCA and UBL can stick to autosampler and tubing, leading

to carry over, and thus affecting the accuracy of our method. This was achieved by
immediately quantifying a blank sample (solvent) after injecting analytes at 200 ng/mL

concentration (upper limit of quantitation). It was found that our method was not subjected
to carry over as expected.
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2.3.3. Quantification of GCA in Human Bile Samples
After developing and validating our method, we applied it to quantify GCA and UBL in
human bile samples collected from four individuals. However, we do not know if samples

were obtained from healthy individuals or diseased patients. It was found that our method
could detect and differentiate the analyte and IS signals from the background noise in most

of the samples. The standard addition curves were constructed for each of all the four bile
samples. The results obtained from four human bile samples was listed in Table 2.5. The

concentration of GCA was found to range from 4.53- 23.95 mM which was almost within

5.04 - 55.04 mM range reported in a study determined using LCMS method [13]. The
concentration of UBL in bile reported in our study 5.07 - 54.98 mM while one UBL in one
of the samples was found to be below LLOQ. However, these values were higher than the

levels, 0.01 -0.150 mM, 0.005 -0.013 pM, 0.014 -0.181 pM as reported previously using
TLC and HPLC methods [9], [22].
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Table 2. 5 Concentration of GCA and UBL in four human bile samples
Human bile sample

Subject 1
Subject 2
Subject 3
Subject 4

Concentration
(mM)
4.53
24.95
9.96
21.48

of
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GCA Concentration of UBL
(mM)
5.54
54.98
5.07
<LLOQ

2.4. Conclusion
We have successfully developed a dilute-and-shoot flow injection MS/MS method
for the quantification of GCA and UBL in human bile using standard addition. Our method

has been validated for linearity, accuracy, precision, matrix effects, LLOQ and carryover,
according to the FDA guidelines. This method offers several benefits for clinical use. First,
it does not require tedious sample purification prior to analysis. Our method utilizes simple

dilution for sample preparation, while not compromising on sensitivity even after 800, 000

fold dilution. Second, our method is accurate and precise without the use of LC separation,
eliminating the carryover problem that which would otherwise require frequently washing
to maintain the column condition. Third, our method does not necessitate blank bile matrix
that is virtually impossible to obtain but is required for the conventional quantitation

method. In addition, our method is fast with a run time of only 2.5 min, enabling high
throughput analyses of over 500 samples a day. To the best of our knowledge, this is the

first flow injection MS/MS method developed for quantifying GCA and UBL in human

bile.
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CHAPTER III

DEVELOPMENT AND VALIDATION OF AN LC-MS/MS METHOD FOR
DETERMINATION OF TEMOZOLOMIDE IN MOUSE BRAIN FOLLOWING

INTRACEREBRAL MICRODIALYSIS
3.1. Introduction

Temozolomide (TMZ) is an anticancer pro-drug that has been approved by the US
Food and Drug Administration for treatment of newly diagnosed glioblastoma multiforme
(GBM) in adults. GBM is a grade IV brain tumor effecting 10 per 100,000 people across

the world. This form of cancer has very poor prognosis and patients usually die within few

months after diagnosis [1]. Administration of TMZ with concurrent radiation therapy
followed by a maintenance dose has been found to increase the life span of GBM patients

from 12.1 to 14.6 months [2,3]. At physiological pH, TMZ hydrolyzes spontaneously to
Methyl-(trazen-1-yl) imidazole-4-carboxamide (MTIC) which further dissociates to form
Diazomethane. Diazomethane is reactive and methylates guanine at the O6 position

forming ‘methylated guanine-thymine’ mismatches and double-stranded breaks,

eventually leading to apoptosis of the cell.
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However, GBM remains incurable because administration of TMZ via intravenous
and oral routes delivers only 35-39% of the drug to the tumor site owing to poor

permeability and abnormal vasculature of brain tumors [4,5]. Furthermore, if higher dose
of TMZ is administered to increase drug delivery, it leads to systemic toxicity worsening
the already compromised lifestyle of the patient. One potential alternative for effective

treatment is targeted drug delivery by intracerebral microdialysis in which TMZ is perfused
directly into the brain tumor region through a semipermeable microdialysis probe [6].

However, microdialysis is mostly utilized as a sampling technique rather than a drug
delivery procedure [7-9]. To assess the potential of intracerebral microdialysis as an

alternative route of administration, a good analytical method is required to quantitate TMZ
first in animal models. Goldwirt et al. and Liu et al described LC-MS methods for

determining TMZ in mouse brain following intraperitoneal administration and focused
ultrasound treatment respectively [10-11]. However, these methods were only partially

successful in extracting TMZ from mouse brain. Though no validation data was published

by Liu et al., Goldwirt et al. reported a mean recovery of 63% and mean matrix effects of
220 %. Therefore, in this work, our aim is to improve recovery of TMZ and minimize

matrix effects of mouse brain tissue for LC-MS/MS quantitation. We hypothesize that poor

extraction of TMZ could be attributed to lack of a lysis buffer and incomplete protein
precipitation. Hence, we augmented homogenization with the help of a lysis buffer,

Proteinase K to release TMZ from mouse brain tissue and achieved a mean recovery of
82%. We were also able to curtail matrix effects to <15% by precipitating proteins in mouse

brain tissue with ethanol. In this study we describe a detailed LC-MS/MS method
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development and validation to determine TMZ in mouse brain following intracerebral brain
microdialysis.

3.2. Experimental

3.2.1. Chemicals

Temozolomide (C6H6N6O2, >98%), Theophylline (as an internal standard, IS,
C7H8N4O2, 99%), formic acid (CO2H2, 98%), ammonium acetate (C2H7NO2, 99.99%) and

HPLC grade ethanol were purchased from Sigma Aldrich (St. Louis, MO, USA). HPLCgrade methanol was obtained from Alfa Aesar (Ward Hill, MA, USA). Proteinase K was

purchased from Qiagen (Hilden, Germany). Deionized water was obtained from Barnstead

D3750 nano pure water purification system by Thermo Scientific (Waltham, MA, USA).
Mice brain samples were obtained and shipped after 12 hours following intracerebral
microdialysis of TMZ.

3.2.2. Preparation of stock solutions and mobile phase

The standard stock solution of TMZ (1 mg/mL) was prepared by dissolving an
appropriate amount of TMZ in known volume of acidic methanol consisting of ammonium

acetate (10 mM)- methanol (1:4 v/v) (pH 3.5). The standard stock IS solution (1 mg/mL)
was prepared by dissolving an appropriate amount of IS in known volume of methanol.
Both the standard stock solutions were stored at -20 °C in separate glass vials. The working
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standard solutions for calibrators (2.04, 6.80, 34.0, 68.0, 170 and 340 ug/mL) and for

quality controls (6.12, 40.8 and 272 ug/mL) were prepared by serial dilution of the stock
solution with mobile phase A. These working standards were used to prepare mouse brain

calibrators and quality controls. The working standard solution of IS (34.0 ug/mL) was
prepared by diluting the standard stock solution of IS with methanol.
Mobile phase A (pH 3.5) was prepared by dissolving 500 uL of formic acid and

ammonium acetate (equivalent to 10 mM) in 100 mL of water and making up the volume

to 500 mL. Mobile phase B consisted of 100% methanol.

3.2.3. Preparation of calibrators and quality controls
TMZ mouse brain calibrators (1.02, 3.40, 17.0, 34.0, 85.0 and 170 ug/g) and QCs
(3.06, 20.4 and 136 ug/g) were prepared by spiking 10 uL of working standard solutions

of TMZ to 20 mg aliquots of blank mouse brain and treated the same way as study samples.

3.2.4. Mouse brain sample preparation
To 20 mg slices of homogenized frozen mouse brain, 10 uL of IS solution (34

ug/mL), 10 uL of formic acid and 40 uL of Proteinase K solution (20 mg/mL) were added,
vortexed for 1 minute and incubated at 37 °C for 1 hour. 270 uL of Ethanol was added to

the lysed samples and incubated at -20 °C for 1 hour to allow protein precipitation. The
samples were then centrifuged at 14000 rpm for 10 minutes. 50 uL of the supernatant was
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transferred into an autosampler vial and the volume was made upto 1 mL with mobile phase
A for subsequent LC-MS/MS analysis.
3.2.5. Instrumentation

High performance liquid chromatography was performed on Shimadzu HPLC unit
(Columbia, MD, USA) which consisted of binary pumps (Nexera LC-30 AD), degasser (a

DUG20A3R), autosampler (SIL-30 AC), column oven (CTO-10AVP) and a controller

(CBM 20A). Mass spectrometric detection was carried out in AB SCIEX 5500 QTRAP
mass spectrometer (Toronto, Canada) equipped with electrospray ionization (ESI) probe
and a syringe pump. The instrument operation, acquisition and processing of data was

performed using AB SCIEX Analyst software (version 1.6.1).

3.2.5.1. Liquid Chromatography

Chromatographic separation of TMZ and IS was achieved at 30 °C on a Waters
symmetry® C18 column (2.1 mm x 150 mm x 3.5 u). Mobile phase A comprised of formic

acid and 10 mM ammonium acetate (pH 3.5) (0.1/100, v/v) and mobile phase B consisted

of methanol. The elution program was as follows: 5% B (initial), 5-30% B (2 min), 30% B
(2 min), 30-90% B (2 min), 90-5% B (2 min) and 5% B (1 min). The flow rate was set at

0.4 mL min-1 and the run time was 8 minutes.
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3.2.5.2. Mass spectrometry
Mass spectrometric detection was carried out in positive electrospray ionization

mode by utilizing multiple reaction monitoring feature of triple quadrupole. The source
and compound dependent parameters were optimized by manual infusion of TMZ and IS
solutions separately into the ionization source. The source dependent parameters were as
follows: curtain gas at 30 psi; collision assisted dissociation gas at high; ion spray voltage

at 5500 V; source temperature at 100 °C; sheath gas at 10 psi and desolvation gas at 10 psi.

The compound dependent parameters were as follows: declustering potential at 150 V;
entrance potential at 10 V; collision energy at 15 eV (TMZ), 25 eV (IS) and collision cell

exit potential at 20 V (TMZ), 10 V (IS). The mass transitions for TMZ were m/z 195.1 -

138.1 (quantifier) 195.1 - 138.1 (qualifier) and for IS was 181.1 - 124.1.

3.3. Results and Discussion

3.3.1. Method development

3.3.1.1. Analyte and IS

Temozolomide chemically 4-methyl-5-oxo-2,3,4,6,8-pentazabicyclo[4.3.0]nona2,7,9-triene-9-carboxamide, has a molecular weight of 195.138 g/mol. It is stable at pH <5
and labile at pH >7 with a pKa value of 10.51 [12]. Theophylline was selected as internal
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standard not only because of its structural similarity to TMZ, but also because it was
significantly less expensive than the deuterated analogs of TMZ.

Theophylline is

chemically 1,3-Dimethyl-3,7-dihydro-1H-purine-2,6-dione with a molecular weight of

180.164 g/mol. Theophylline has a pKa value of 7.82 and is stable in the pH range of 1-12
[13-14].

3.3.1.2. Mass spectrometric detection
Detection of TMZ and IS was carried out using a triple quadrupole mass

spectrometer. Since TMZ and IS readily protonated in the acidic mobile phase, positive

electrospray mode was chosen for ionization. As shown in fig. 3.1, TMZ and the IS
generated protonated precursor ions [TMZ + H]+ at m/z 195.1 and [IS + H]+ at m/z 181.1
respectively in the ionization source. These precursor ions were further fragmented in the

collision cell into product ions at m/z 138.1 and 110.0 for TMZ and at m/z 124.1 for the IS.
Quantitation was done in multiple reaction monitoring (MRM) mode with mass transitions
of m/z 195.1 ^ 138.1 for TMZ and m/z 181.1 ^ 124.1 for the IS. To ensure that only TMZ
and no other ions were quantified, we also monitored an additional transition of m/z 195.1
^ 110.0 as a qualitative transition for increased confidence in identifying the target

analyte.
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Figure 3. 1 The mass spectra of TMZ and IS along with their probable fragmentation
pattern in ESI+ mode. (A) Precursor ion of TMZ - m/z 195.1, product ions of TMZ - m/z
138.1 (quantifier) and 110.0 (qualifier). (B) Precursor ion of IS - m/z 181.1, product ion
of IS - m/z 124.1.
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3.3.1.3. Liquid chromatographic separation

Since TMZ and IS are hydrophobic, reverse phase C-18 columns were chosen for

chromatographic separation in a HPLC unit. Columns such as Agilent Poroshell 120 EC-

C18 column (Agilent Technologies Inc., Santa Clara, CA, USA), Phenomenex Luna® C18
column (Phenomenex Inc., Torrance, CA, USA) and Waters Symmetry® C18 column

(Waters Corporation, Milford, MA, USA) were experimented. Among them Waters
Symmetry® C18 column demonstrated best peak shape and symmetry and hence was

chosen for analytical separation. Because TMZ degrades at pH >5, mobile phase A was

maintained at pH 3.5 using 10 mM ammonium acetate and 0.1% formic acid which also
helped in improved ionization. Methanol was used as organic solvent to provide optimum
strength for eluting TMZ and IS from the C-18 column.
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Figure 3. 2 The LC-MS/MS chromatograms of TMZ and IS in mouse brain. Double blank
(TMZ and IS absent) chromatograms of (A) TMZ quantifier (B) IS. Single blank (TMZ
absent and IS at 17 ^g g-) chromatograms of (C) TMZ quantifier (D) IS. LLOQ (TMZ at
1.02 ^g g-and IS at 17 ^g g-) chromatograms of (E) TMZ quantifier (F) IS. Calibrator (TMZ
at 17 ug g-and IS at 17 ug g-) chromatograms of (G) TMZ quantifier (H) IS.
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3.3.1.4. Sample preparation

The first step in sample preparation was addition of 10 pL of formic acid to prevent

hydrolysis of TMZ at pH < 5 by maintaining a ~pH 3.5. Next, in order to achieve high

percent recovery of TMZ, we tested homogenization with various lysis buffers such as
SDS, RIPA, guanidine hydrochloride and Proteinase K out of which Proteinase K gave the
best results. We further optimized the volume by treating equal weight frozen brain aliquots
with 0.4, 4 and 40 pL of Proteinase K and incubated at 37 °C for 1 hour. 40 pL of Proteinase

K treated sample produced most clear solution and hence was chosen for sample
preparation.

In addition to water, mouse brain consists of about 25% proteins, 11%
phospholipids and 4% cholesterol [15]. Protein precipitation is one of the common sample
preparation methods to remove proteins from the sample matrix [16,17]. However,

Goldwirt et al.’s method suffered from severe matrix effects of about 220% possibly due
to incomplete removal of proteins from the matrix. The amount of zinc sulfate used was

lower than the recommended ratio of 2:1 (zinc sulfate to matrix) which might have resulted
in incomplete protein precipitation [18]. Additionally, zinc sulfate was also believed to
precipitate drug molecules along with proteins present in tissues [19]. To address this issue,

we evaluated alternative protein precipitating agents, trifluoro acetic acid (TFA) and
ethanol.

Equal weight frozen brain aliquots were first acidified with formic acid, spiked with
TMZ, IS and lysed with Proteinase K. For TFA protein precipitation, one set of the above

samples was treated with 40 pL of TFA, diluted with 130 pL of water and incubated at 4°C
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for 1 hour. The second set of samples was treated with 270 uL of ethanol and incubated at

-20 °C for 1 hour. All samples were then centrifuged and processed the same way as
described in section 2.4. Thereafter, the peak area ratios of both sample sets were compared
against those of neat solution (without matrix). The peak area ratios of ethanol treated
samples were consistent with negligible matrix effects and suggested higher recovery

compared to those of TFA treated samples. Hence ethanol was chosen for protein
precipitation.
3.3.2. Method validation

The LC-MS method was validated in accordance with the guidelines established by
the US FDA for industry on bioanalytical method validation [20].

3.3.2.1. Selectivity and specificity

Specificity is defined as the ability to measure exclusively TMZ in the presence of
other components in addition to matrix components. To ensure specificity, in addition to

m/z 195.1 ^ 138.1 (quantifier), another mass transition m/z 195.1 ^ 110.0 (qualifier) was
monitored throughout the analysis.

Selectivity is defined as the ability ofthe method to determine analyte in the sample
without interferences from matrix components. To evaluate selectivity, six double blanks
and single blanks from six different mouse brains were analyzed. for interferences at

retention times of TMZ and IS. As shown in Fig.2, tiny peaks were detected at the retention
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time of TMZ and IS in double and single blanks, but they are insignificant as their peak

area was < 10% of that of LLOQ.

3.3.2.2. Linearity and Lower limit of quantitation (LLOQ)

The relationship between concentration of TMZ in the calibrators and detector
response was studied in the range of 1.02 - 170 gg/g. A standard calibration curve for
TMZ was constructed using a double blank, a single blank and six non-zero calibrators in

mouse brain matrix (1.02, 3.40, 17.0, 34.0, 85.0 and 170 ug/g). The peak area ratios of
TMZ to IS were plotted against the concentrations of TMZ in mouse brain calibrators with

1/x as weighing factor. The equation derived from the calibration curve was y = 0.0356x
+ 0.2771 with a correlation coefficient of 0.9975. As shown in table 3.1, the accuracy and

precision for all calibrators were within limit (20% for the LLOQ and 15% for other non

zero calibrators) except ULOQ which was slightly higher.
Lower limit of quantitation (LLOQ) is defined as the lowest analyte concentration
in the matrix that can be determined with acceptable accuracy and precision. The absolute

peak area of TMZ at 1.02 ug/g i.e., the LLOQ was more than five times of the absolute
peak area of TMZ in double and single blanks as required by the US FDA. The LLOQ was
further evaluated in five different mouse brain samples on the same day and five different

days for intra and inter-day accuracy and precision respectively. As shown in table 3.2,
accuracy and precision of LLOQ were 6% and 15% respectively which were below the

20% limit set by the FDA.
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Table 3. 1 Linearity of TMZ from six non-zero calibrators in three mouse brain samples
measured over three different days (n=3).
Spiked concentration (ug/g)

Determined concentration ± SD (ug/g)

%RE

%CV

1.02
3.40
17.0
34.0
85.0
170

0.97 ± 0.13
3.27 ± 0.12
19.2 ± 0.45
37.0 ± 2.03
88.2 ± 3.30
162 ± 3.76

-5
-4
13
9
4
-5

11
14
14
8
14
17

%RE (percent relative error) = [(determined concentration - spiked concentration)/(spiked
concentration)] x 100
%CV (percent coefficient of variation) = (standard deviation/mean) x 100
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CALIBRATION CURVE (N=3)

600

Figure 3. 3 Calibration curve of TMZ (n=3)
Correlation coefficient, R2 = 0.9975
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Table 3. 2 Lower limit of quantitation (LLOQ) of TMZ determined in five individual
mouse brain samples on the same day and five different days (n=5).

LLOQ
Intra-day
Inter-day
Spiked
Determined
%RE %CV Determined
%RE %CV
concentration concentration
concentration
(ug/g)
± SD (ug/g)
± SD (ug/g)
1.02
1.06 ± 0.05
4
5
1.09 ± 0.07
6
15
%RE (percent relative error) = [(determined concentration - spiked concentration)/(spiked
concentration)] x 100
%CV (percent coefficient of variation) = (standard deviation/mean) x 100
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3.3.2.3. Accuracy and precision
Accuracy is defined as the degree of closeness of the determined value to the true

value. Precision is defined as the closeness of agreement among series of measurements
obtained from multiple sampling of the same homogeneous sample. For this study, we

estimated intra-day and inter-day accuracy and precision in three QCs at three

concentrations (3.06, 20.4 and 136 gg/g) prepared from five individual mouse brains.
Intra-day accuracy and precision were determined by five sets of three QCs prepared from
five individual mouse brains on the same day. Inter-day accuracy and precision were

determined by five sets of three QCs prepared from five individual mouse brain samples

on five different days. As shown in table 3.3, intra-day accuracy expressed as %RE was <
7% and precision expressed as %CV was < 3%. The inter-day accuracy was < 6% and
precision was < 10 %. It should be noted that even though analyses were done using QCs

from five individual mouse brain samples, all values were well below the 15% limit set by
the FDA demonstrating the accuracy and precision of the method.
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Table 3. 3 Accuracy and precision of TMZ in five individual blank mouse brain samples
measured on the same day and five different days (n=5).

Intra-day
Determined
concentration
± SD (ug/g)

Inter-day
Determined
%RE
%CV
QC
level
concentratio
n
± SD (ug/g)
3.06
3.13 ± 0.05
2
2
3.27 ± 0.13
4
10
LQC
MQC
20.4
19.0 ± 0.63
-7
3
19.2 ± 0.66
-6
10
136
137 ± 4.64
1
3
141 ± 4.87
2
9
HQC
%RE (percent relative error) = [(determined concentration - spiked concentration)/(spiked
concentration)] x 100
%CV (percent coefficient of variation) = (standard deviation/mean) x 100
Spiked
concentration
(ug/g)

%RE
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%CV

3.3.2.4. Matrix effect and recovery

Matrix effect is defined as the effect on the method caused by other components in

a study sample except the analyte. For this study, we evaluated the absolute and relative
matrix effects in five individual mouse brain samples in three QCs at three concentrations
(3.06, 20.4 and 136 gg/g). The absolute matrix effect of TMZ was determined by

calculating the percentage of mean peak area of TMZ at three concentrations in extracted
mouse brain matrix over mean peak area of TMZ in neat solution. The relative matrix
effects were evaluated by calculating percentage of mean peak area ratio of TMZ and IS at

three concentrations in the extracted mouse brain matrix over that of TMZ and IS in neat
solution. As shown in table 3.4, the absolute matrix effects were within 85-108% and
relative matrix effects were within 96-102%. All the values were below the 15% limit set

by the FDA suggesting that we have successfully addressed the matrix effect issue suffered
by Goldwirt et al.’s method by using ethanol to precipitate out proteins.
Recovery is defined as the extraction efficiency of the method, expressed as

percentage of the known amount of the analyte carried through the extraction steps of the
method [21]. Recovery was studied by assessing the absolute and relative recoveries in two
individual mouse brain samples in three QCs at three concentrations (3.06, 20.4 and 136
gg/g). Absolute recovery was estimated by calculating the percentage mean peak area of

TMZ spiked in mouse brain matrix before extraction over that of TMZ spiked in extracted
mouse brain matrix. Relative recovery was evaluated by calculating the percentage of mean
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Table 3. 4 Absolute, relative and IS matrix effect in five individual mouse brain samples
(n=5).

Mouse
brain
sample
1

2

3

4

5

QC level

LQC
MQC
HQC
LQC
MQC
HQC
LQC
MQC
HQC
LQC
MQC
HQC
LQC
MQC
HQC

Spiked
concentration
(ug/g)
3.06
20.4
136
3.06
20.4
136
3.06
20.4
136
3.06
20.4
136
3.06
20.4
136

Absolute
matrix effect
(%)
97 ± 4.67
98 ± 2.29
98 ± 1.30
96 ± 1.16
94 ± 1.20
90 ± 0.84
106 ± 1.77
94 ± 0.55
85 ± 1.57
108 ± 2.71
95 ± 2.40
91 ± 0.13
103 ± 2.69
99 ± 1.50
92 ± 0.55

IS
matrix effect
(%)
98 ± 1.57
101 ± 1.85
102 ± 0.99
97 ± 2.06
95 ± 2.51
89 ± 1.33
104 ± 3.76
94 ± 0.32
82 ± 0.45
111 ± 2.35
98 ± 0.41
94 ± 1.18
101 ± 0.87
101 ± 1.96
91 ± 1.27

Relative matrix
effect
(%)
98 ± 4.23
98 ± 0.76
96 ± 1.37
99 ± 3.25
98 ± 3.14
101 ± 0.84
102 ± 5.35
100 ± 0.31
103 ± 2.13
98 ± 1.53
97 ± 2.72
97 ± 1.19
102 ± 2.97
99 ± 3.34
100 ± 1.17

Absolute matrix effect = [(mean peak area of TMZ in extracted mouse brain/mean peak
area of TMZ in neat solution)] x 100.
IS matrix effect = [(mean peak area of IS extracted mouse brain /mean peak area of IS in
extracted neat solution)] x 100.
Relative matrix effect = [(mean peak area ratio of TMZ/IS in extracted mouse brain/mean
peak area ratio of TMZ/IS in neat solution)] x 100.
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Table 3. 5 Absolute, relative and IS recovery in two individual mouse brains (n=2).

Mouse
brain
sample
1

2

QC level

LQC
MQC
HQC
LQC
MQC
HQC

Spiked
concentration
(ug/g)
3.06
20.4
136
3.06
20.4
136

Absolute
Recovery
(%)
80 ± 0.03
85 ± 0.02
79 ± 0.01
81 ± 0.00
84 ± 0.02
84 ± 0.02

IS
Recovery
(%)
71 ± 0.01
78 ± 0.02
72 ± 0.00
67 ± 0.02
78 ± 0.01
77 ± 0.02

Relative
Recovery
(%)
113 ± 0.05
109 ± 0.02
109 ± 0.02
121 ± 0.03
108 ± 0.02
108 ± 0.02

Absolute recovery = [(mean peak area of TMZ in mouse brain/mean peak area of TMZ in
extracted mouse brain matrix)] x 100.
IS recovery = [(mean peak area of IS in mouse brain/mean peak area of IS in extracted
mouse brain matrix)] x 100.
Relative recovery = [(mean peak area ratio of TMZ/IS in mouse brain/mean peak area ratio
of TMZ/IS in extracted mouse brain matrix)] x 100.
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peak area ratio of TMZ and IS spiked in mouse brain matrix before extraction over that of
TMZ and IS spiked in the extracted mouse brain matrix.

As shown in table 3.5, the mean absolute recovery was 82% and mean relative
recovery was 111%. These values were higher than those reported by Goldwirt et al. who
reported a mean recovery of 63% suggesting that our method has improved the recovery

of TMZ from mouse brain by 19% which could be attributed to the use of a lysis buffer to
aid in homogenization.

3.3.2.5. Stability studies
Stability is defined as the measure of intactness of analyte in the sample matrix

under specific storage and use conditions relative to the starting material for given time

intervals. Studies were conducted to assess stock solution, autosampler, benchtop and

freeze-thaw cycle stabilities. The stability of TMZ in the autosampler, benchtop and freeze
thaw samples was expressed as percentage of measured mean peak area ratio of TMZ to

IS against those of TMZ to IS in freshly prepared samples. Stock solution stability was
assessed by keeping the stock solution (1 mg/mL) of TMZ at room temperature (25 °C) on
bench top for 12 hours before diluting it to 10 and 100 ng/mL. Bench top and autosampler

stability studies were performed by leaving QCs on bench top at 25 °C for 12 hours and
autosampler at 15 °C respectively. Three freeze-thaw cycles were conducted by freezing

QCs at -20 °C for 12 hours followed by thawing them unassisted at 25 °C.
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Table 3. 6 Stability studies of TMZ under various test conditions (n=3).

Test
conditions

Sample

Nominal
Temperature
Concentration

Duration

%
Recovery ±
SD
116 ± 0.02a

10 ng/mL
25 °C
Stock
12 h
solution
125 ± 0.04a
Stock
100 ng/mL
solution
25 °C
12 h
100 ± 0.04b
Bench top
LQC
3.06 bg/g
102 ± 0.05b
HQC
136 bg/g
15 °C
18 h
109 ± 0.06b
Autosampler LQC
3.06 bg/g
90
± 0.04b
HQC
136 bg/g
Freeze-thaw LQC
-20 to 25 °C Frozen for 123 ± 0.08b
3.06 bg/g
12 h
cycles
116 ± 0.04b
HQC
136 bg/g
a %Recovery = [mean peak area of TMZ in stability sample/ mean peak area of TMZ in
fresh sample] x 100.
b %Recovery = [mean peak area ratio of TMZ/IS in stability sample/ mean peak area ratio
of TMZ/IS in fresh sample] x 100.

Bench top
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The stability of samples under various test conditions described above was
expressed as percent recovery (%RE) and were presented in table 3.6. Stock solution
showed a recovery of 116% when diluted to 10 ng/mL and 125 % when diluted to 100

ng/mL indicating that it should not be stored at room temperature for more than 12 hours.

The %RE of QCs were < 10% suggesting that QCs were stable for 12 hours at bench top
and 18 hours in the autosampler. The %RE for LQC was 2% higher than the 20% limit set

by FDA signifying that freezing and thawing QCs should be kept under three cycles.

3.3.2. Method application

The above method has been applied to determine TMZ in eight mouse brain
samples subjected to intracerebral micro dialysis. As shown in table 3.7, the concentration

of TMZ in the eight brain samples collected after 12 hours was below LLOQ. While no
data was available on pharmacokinetics of intracerebral microdialysis of TMZ in mice

brain, Goldwirt et al. published a concentration-time profile where concentration of TMZ
reached almost zero at 4 hours after intra peritoneal administration. This suggests that TMZ

could have been possibly converted into its metabolites long before the sample have been

collected. Hence, we conducted another study by injecting 40 ug of TMZ into a mouse
brain using a 1cc syringe fitted with a 31 g, 5/16inch needle (similar gauge size as that of

the microdialysis probe) and analyzed it immediately. The determined amount was 39.55
ug with a percent recovery of 99%.
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3.4. Conclusion

In conclusion, a high recovery yielding LC-MS/MS method for quantitative

determination of TMZ in mouse brain has been developed and validated for the first time.

The method consisted of two-step extraction process involving a lysis buffer for
homogenization and protein precipitation with ethanol, both crucial for achieving 82%
recovery and matrix effects within 15%. The method developed was applied to study

samples and might be useful in determining the amount of TMZ in mouse brain in order to

evaluate intra cerebral microdialysis as a potential alternate route of administration.
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CHAPTER IV
INVESTIGATION OF THE APPLICABILITY OF DIGESTION USING ASPARTIC

ACID N ENDOPEPTIDASE FOR IDENTIFICATION OF VARIANTS OF DESGAMMA-CARBOXY PROTHROMBIN BY LC-MS

4.1. Introduction
Hepatocellular carcinoma (HCC) is the second leading cause of cancer related

deaths in the world and is the fifth most common cancer with over half a million cases

diagnosed a year globally [1]. HCC is usually diagnosed at late stages and patients are
reported to have a maximum post-diagnostic survival period of five years [2]. Infection

with hepatitis B or C viruses, alcohol-related cirrhosis and non-alcoholic steatohepatitis are

found to be major risk factors of HCC [3]. Symptoms of HCC include right upper quadrant
pain, weight loss, jaundice, palmar erythema, gynecomastia, portal hypertension, anemia,

etc. [4]. Management of HCC is dependent on the nature of tumor, ranging from surgical

resection, liver transplantation during initial stages to chemotherapy in late stages [2]. HCC
screening is performed by using ultrasound of the liver which is challenging because of

differences in the interpretations among radiologists and by magnetic resonance imaging
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which is expensive [2], [4]. Alfa feto protein (AFP) and Des-gamma-carboxy-prothrombin
(DCP) also known as PTB induced by Vitamin K absence-II (PIVKA-II) have been

investigated and widely used as tumor markers for HCC [5]-[19].

4.1.1 Biosynthesis of DCP from prothrombin precursor
prothrombin (PTB) or clotting factor II is an important protein involved in the

coagulation of blood. It has a molecular weight of 72 kDa and is present at a concentration
of approximately 0.1 mg/mL in the plasma of healthy individuals [20]. In the coagulation
cascade, prothrombinase complex converts PTB to thrombin which converts soluble
fibrinogen to insoluble fibrin ultimately leading to coagulation of blood. PTB is a single

chain glycoprotein comprising of 579 amino acid residues which are arranged into gamma
carboxyglutamic (Gla) domain (residues 1-46), kringle-1 (residues 65-143), kringle-2

(residues 170-248) and protease domain comprising of A chain (residues 285-320) and
catalytic B chain (residues 321-579) [21]. In the Gla domain of PTB, there are present ten
post translationally modified glutamic acid residues located at 6, 7, 14, 16, 19, 20, 25, 26,
29 and 32 positions. Under physiological conditions, prothrombin precursor (622 amino

acids) is converted to PTB (579 amino acids) by post translational carboxylation and
removal of a signal peptide and a propeptide in the lumen of the endoplasmic reticulum of

liver cells before its secretion into the blood. [22]. During this process, glutamic acid
residues (Glus) present in the Gla domain are converted to Y-carboxy glutamic acid residues
(Glas) by a Vitamin K dependent enzyme, Y-glutamyl carboxylase as shown in fig 4.1.
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HC — COOH

COOH

Figure 4. 1 Post translational modification of Glutamic acid (Glu) to gamma carboxy
glutamic acid (Gla) by Vitamin K dependent gamma carboxylase enzyme (image adapted
from reference [23])

In a healthy individual, gamma-carboxylation occurs at all the ten Glus in the Gla domain

of PTB and is essential for the anticoagulant activity of PTB. Uehara et al reported that ten
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Glus are carboxylated in the order of 26, 25, 16, 29, 20, 19, 14, 32, 7 and 6 positions from
the N-terminus [24]. Fig. 4.2A shows the complete amino acid sequence of PTB with all

ten Glus (represented by E) post translationally modified into Glas (represented by y) in

the Gla domain and fig. 4.2B shows different domains of PTB and a part of the polypeptide
in Gla domain containing ten Glas. y-glutamyl carboxylase is a Vitamin K dependent

enzyme and its activity is lowered when Vitamin K is inadequate in conditions such as
Vitamin K deficiency, hepatocellular carcinoma or by Vitamin K antagonists. This leads
to incomplete carboxylation of Glus in the Gla domain leaving all ten or some Glus not

converted to Glas. The resulting abnormal PTB molecules with no or partial carboxylation
are collectively called as Des-carboxy prothrombin (DCP) [61]. DCP lacks the ability to
interact with other clotting factors. DCP is also known as PIVKA-II (Protein Induced by

Vitamin K deficiency or Antagonist-II) as it was originally discovered in the plasma of
Vitamin K deficient or phenprocoumon, (a Vitamin K antagonist) treated animals along
with other abnormal clotting factors IX and X resulting from incomplete carboxylation

[25]. Thus, DCP contains several variants which differ in the Glu content in their Gla
domains as shown in the following fig. 4.3. DCP is produced by malignant hepatocyte and

various mechanisms for production of DCP in HCC have been proposed [17]. Hypoxia
occurs in HCC cells that may lead to recycling of Vitamin K leading to diminished activity

of y-glutamyl carboxylase enzyme ultimately resulting in the production of DCP [20].

A)
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B)

ANTFLyyVRKGNLyRyCVyyTCSYyyAFyALySSTATDVFWAKYTACETARTPRD

KLAACLEGNCAEGLGTNYRGHVNITRSGIECQLWRSRYPHKPEINSTTHPGADLQENF

CRNPDSSTTGPWCYTTDPTVRRQECSIPVCGQDQVTVAMTPRSEGSSVNLSPPLEQCV
PDRGQQYQGRLAVTTHGLPCLAWASAQAKALSKHQDFNSAVQLVENFCRNPDGDEE

GVWCYVAGKPGDFGYCDLNYCEEAVEEETGDGLDEDSDRAIEGRTATSEYQTFFNPR

TFGSGEADCGLRPLFEKKSLEDKTERELLESYIDGRIVEGSDAEIGMSPWQVMLFRKSP
QELLCGASLISDRWVLTAAHCLLYPPWDKNFTENDLLVRIGKHSRTRYERNIEKISMLE
KIYIHPRYNWRENLDRDIALMKLKKPVAFSDYIHPVCLPDRETAASLLQAGYKGRVTG
WGNLKETWTANVGKGQPSVLQVVNLPIVERPVCKDSTRIRITDNMFCAGYKPDEGKR
GDACEGDSGGPFVMKSPFNNRWYQMGIVSWGEGCDRDGKYGFYTHVFRLKKWIQK

VIDQFGE

Figure 4. 2 A) Structure of prothrombin B) Amino acid sequence of prothrombin
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E

E A

Figure 4. 3 Portions of DCP variants containing 1-10 Glus arranged in the order of
carboxylation proposed by Uehara et al (bottom to top).

4.1.2 DCP as a risk marker for HCC
Liebman et al found that DCP was present in the plasma of 90% of HCC patients
at a mean level of 900 ng/mL while it was lower (10 ng/mL) chronic active hepatitis and
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negligible in healthy subjects [5]. Since then, several studies have been conducted to

evaluate the utility of DCP as a biomarker for HCC. Literature review reveals that
sensitivity values varied between 28-90% and specificity between 44%-100%. Levels of
DCP did not correlate with those of AFP, which is the most widely used biomarker for

HCC as both of them have different mechanisms. Studies were also performed to compare
the sensitivity and accuracy of DCP with AFP. DCP exhibited more sensitivity in most

studies but some studies showed that AFP is more sensitive than DCP. While AFP was

more accurate in diagnosing small tumors, DCP diagnosed large tumors and early stage
HCC more accurately than AFP [26]. Tumor relapse and metastasis are found to be more
in patients with positive for DCP. DCP has been approved by the FDA as a risk marker for

HCC and is used in combination with AFP and AFP L3 (lens culinaris agglutinin-reactive

AFP) in Asia for early detection of HCC [27]. DCP was predicted to stimulate and
metastasize HCC growth by activating abnormal signaling pathways [20]. However, very
little information is available on the biochemical role of the different variants in the

progression of HCC.
Higher levels of DCP are not only found in HCC patients but also in non-HCC

conditions such as obstructive jaundice, Vitamin K deficiency and in patients on warfarin
therapy [28]. Though Vitamin K has been found to have an apoptotic role in HCC,

administration of Vitamin K could not prevent the recurrence of the cancer. Hence, the

interrelationship between Vitamin K deficiency, elevated DCP and HCC still needs to be
investigated. Currently, the concentration of DCP in serum is estimated by immunoassays
that use MU-3 antibodies. A study conducted by Naraki et al revealed that DCP produced

in HCC consisted of variants with 6-10 Glu residues [29]. In the same study it has been

96

found that the epitope of MU-3 antibodies consisted of amino acid residues 17-27 which
included Es at 19, 20, 25 and 26. MU3 antibodies are found to bind with those variants that

had at least 6Es (and with 2Es present at 19 and 20). However, DCP variants produced in
vitamin K deficiency, consist of 2-9 Glu residues and also react partially with MU-3
antibodies, leading to false positive results [17]. Previous studies aimed at investigating the

level of total DCP variants in HCC and non-HCC conditions, but very little information is
available regarding the distribution of different variants and their levels in serum. It is still
unknown which variant among the variants could serve as a highly specific biomarker for

HCC. Hence, a study of distribution of DCP variants in the sera of HCC patients and
Vitamin K deficient patients could determine the best variant that can serve as a sensitive
and specific biomarker of HCC.

4.1.3 Identification of variants of DCP using middle-down approach

Top-down and bottom-up proteomics are widely used approaches to study variants
of proteins. A top down approach involves the analysis of intact protein (>10k Da) and

requires expensive and high-resolution mass spectrometers. A bottom-up approach

involves the analysis of peptides (< 3kDa) generated by Tryptic digestion of proteins.
Though it is widely used, a bottom up approach is not ideal for studying PTMs due to the

short length of the peptides [30]. In this study, we have chosen a middle-down approach
(which involves analysis of peptides of 3-10 kDa length) to identify different variants of
DCP as it is more suitable and convenient if a single peptide that contains all ten Glus or

Glas can be produced by subjecting the protein to enzymatic digestion. For this purpose,
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we have chosen PTB as the analyte for quantification as it only differs from DCP in the
extent of carboxylation at ten Glus and is readily available unlike DCP which is difficult

to obtain. Detection of the peptide containing 10 Glas in PTB will allow the study of
distribution of different variants of DCP in Vitamin K and HCC serum samples based on
the differences in their molecular weights (and hence m/Z). Though Trypsin is a widely

used enzyme owing to its high specificity and reproducibility, it is not preferred in this

study because it cleaves in between the 10 Glas producing three different peptides as shown
in table 4.1. Therefore, we performed an in silico digestion of PTB with various enzymes

and chemicals using ExPASy: SIB bioinformatics resource portal as shown in table 4.1 and

searched for enzymes or chemicals that could produce a single peptide retaining all ten
Glus [28]. As can be seen in the same table, BNPS-Skatole, Factor Xa, Aspartic acid N
endopeptidase, Cyanogen bromide, Formic acid, Iodosobenzoic acid and Proline

endopeptidase produced single peptides with all ten Glus. Aspartic acid N endopeptidase
was selected for this study because it generated shortest peptide consisting of 37 amino

acids which is more likely detectable than the other peptides within the dynamic range of
mass spectrometer.

Table 4. 1 Peptides obtained by performing in-silico digestion using different enzymes
[28]
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Enzyme

Trypsin

Arg-C
proteinase

Number of Amino acid sequence of peptides
peptides
containing 10
Glus
3
ANTFLEEVR

LysC

Neutrophil
elastase

Pepsin

Thermolysin

9

GNLER

5

ECVEETCSYEEAFEALESSTATDVFWA
K
ANTFLEEVR

28

KGNLER

6

ECVEETCSYEEAFEALESSTATDVFWA
KYTACETAR
ANTFLEEVRKGNLERECVEETCSYEEA
FEALESSTATDVFW
LEEVRKGNLERECVEETCSY

36
41

EEAF

20

EALESSTATDVF

4

EALESSTATDVF

12

3

ANTFLEEVR

9
6
36

2

KGNLER
ECVEETCSYEEAFEALESSTATDVFWA
KYTACETAR
ANTFLEEVRK

33

5

GNLERECVEETCSYEEAFEALESSTAT
DVFWAK
NTFLEEV
RKGNLERECV
EETCSYEEA

10
9

FEA

3

LESSTA
EEVRKGNL

6
8

ERECVEETCSYEEA

14

EA

2

ESSTATDV

8

LEEVRKGN

8

LEREC
VEETCSYEEA

5
10

3

1
BNPSSkatole
Chymotrypsin 4

Clostripain

Number
of amino
acids

4

5
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9

4

10

7

Asp-N
endopeptidase
CNBr

1

Formic acid

1

LysN

2

Iodosobenzoi
c acid
NTCB

Proline
endopeptidase

1

1
3

1

FEA

3

LESST

5

ANTFLEEVRKGNLERECVEETCSYEEA
FEALESSTAT
ANTFLEEVRKGNLERECVEETCSYEEA
FEALESSTATDVFWAKYTACETARTPR
DKLAACLEGNCAEGLGTNYRGHVNIT
RSGIECQLWRSRYPHKPEINSTTHPGA
DLQENFCRNPDSSTTGPWCYTTDPTVR
RQECSIPVCGQDQVTVAM
ANTFLEEVRKGNLERECVEETCSYEEA
FEALESSTATD
ANTFLEEVR

37

KGNLERECVEETCSYEEAFEALESSTA
TDVFWA
ANTFLEEVRKGNLERECVEETCSYEEA
FEALESSTATDVFW
ANTFLEEVRKGNLERE

33
41

CVEET

5

CSYEEAFEALESSTATDVFWAKYTA

25

ANTFLEEVRKGNLERECVEETCSYEEA
FEALESSTATDVFWAKYTACETARTPR
DKLAACLEGNCAEGLGTNYRGHVNIT
RSGIECQLWRSRYPHKP
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100

152

38
9

16

4.1.4 Feasibility of digestion using Aspartic acid N endopeptidase

Aspartic acid N endopeptidase (Asp-N) is a metalloproteinase (EC 3.4.24.33)

produced by Pseudomonas fragi. It cleaves peptide bonds at N terminal to Aspartic acid
and Cysteic acid residues [31]. However, if Cysteines are alkylated, cleavage is specific at

Aspartic acid residues, though cleavage at Glus to a lesser extent (2000 fold less) was
observed when digestion times are longer [32]. Because cleavages is specific to only one

residue, Asp-N produces longer peptides and is used in middle-down proteomics or in
combination with Trypsin and other proteases for achieving superior sequence coverage.
In addition to native Asp-N isolated from Pseudomonas fragi, recombinant version cloned

from Stenotrophomonas maltophilia and expressed in E coli is commercially available and
is found to have better sequence coverage as reported by the manufacturer. In our study,

we have investigated digestion efficiency with both forms. The desirable pH range for

optimal activity of Asp-N is 4.0 to 9.0. In this work, our goal is to investigate the feasibility
of employing Asp-N to digest PTB in order to study the distribution of different variants
of DCP in human sera. Specifically, we aim to investigate the digestion efficiency of AspN by evaluating the sequence coverage and overall intensities of the resulting peptides of

prothrombin. Fig. 4.4 shows peptides and cleavage sites of PTB by Asp-N.
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ANTFLEEVRKGNLERECVEETCSYEEAFEALESSTAT|DVFWAKYTACETARTPR|DKLAACLEG
NCAEGLGTNYRGHVNITRSGIECQLWRSRYPHKPEINSTTHPGA |DLQENFCRNP|DSSTTGPWC
YTT|DPTVRRQECSIPVCGQ|DQVTVAMTPRSEGSSVNLSPPLEQCVP|DRGQQYQGRLAVTTHG
LPCLAWASAQAKALSKHQ|DFNSAVQLVENFCRNP|DG|DEEGVWCYVAGKPG|DFGYC|DLNYC
EEAVEEETG|DGL|DE|DS|DRAIEGRTATSEYQTFFNPRTFGSGEA|DCGLRPLFEKKSLE|DK
TERELLESYI|DGRIVEGS|DAEIGMSPWQVMLFRKSPQELLCGASLIS|DRWVLTAAHCLLYPP
W|DKNFTEN|DLLVRIGKHSRTRYERNIEKISMLEKIYIHPRYNWRENL |DR|DIALMKLKKPVA
FS|DYIHPVCLP|DRETAASLLQAGYKGRVTGWGNLKETWTANVGKGQPSVLQVVNLPIVERPVC
K|DSTRIRIT|DNMFCAGYKP|DEGKRG|DACEG|DSGGPFVMKSPFNNRWYQMGIVSWGEGC|D
R|DGKYGFYTHVFRLKKWIQKVI|DQFGE

Figure 4. 4 Cleavage sites (represented by | ) and expected peptides of PTB after
digestion with Asp-N
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4.2 Experimental

4.2.1 Chemicals

PTB (>95%), Ammonium bicarbonate (NH4)HCO3, iodoacetamide (C2H4INO) and
formic acid (COOH2) were purchased from Sigma Aldrich. Aspartic acid endopeptidase

and recombinant Aspartic acid endopeptidase (Asp-N) were obtained from Promega
Corporation (Madison, WI, USA). Trypsin (MS Grade) was purchased from Thermofisher

Scientific (Waltham, MA, USA). Urea (CH4N2O) was purchased from VWR chemicals,

dithiothrietol (C4H10O2S2) was purchased from MP Biomedical (Solon, OH, USA). HPLCgrade acetonitrile (C2H3N) and trifluoro acetic acid (CF3CO2H) was obtained from Alfa

Aesar (Ward Hill, MA, USA). C18 ZipTips and amicon centrifugal spin filters were
obtained from Millipore sigma (Burlington, MA, USA). Deionized water was obtained

from Barnstead D3750 nano pure water purification system by Thermo Scientific
(Waltham, MA, USA).

4.2.2 Preparation of stock and working standard solutions

PTB was dissolved in water to obtain a 1.0 mg/mL solution which was stored at 80 °C as single use 50 uL aliquots to avoid degradation likely caused by multiple freeze

thaw cycles. Native Asp-N and recombinant Asp-N were dissolved separately in water to
obtain 40 ug/mL solutions which were stored at -80 °C as single use 10 uL aliquots to avoid

degradation likely caused by multiple freeze-thaw cycles.
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4.2.3 . Instrumentation
High performance liquid chromatography was performed on Shimadzu HPLC unit
(Columbia, MD, USA) which consisted of binary pumps (Nexera LC-30 AD), degasser (a

DUG20A3R), autosampler (SIL-30 AC), column oven (CTO-10AVP) and a controller

(CBM 20A). Mass spectrometric detection was carried out in AB SCIEX 5500 QTRAP
mass spectrometer (Toronto, Canada) equipped with electrospray ionization (ESI) probe
and a syringe pump. The instrument operation, acquisition and processing of data was

performed using AB SCIEX Analyst software (version 1.6.3).

4.2.3.1. Liquid Chromatography
Chromatographic separation of peptides was achieved at 30°C on a Waters
XBridge™ C18 column (1.0 mm x 100 mm x 3.5 u). For LC-MS analysis in positive mode,

mobile phase A consisting of formic acid in water (0.1/100, v/v) and mobile phase B

consisting of acetonitrile were used. During the optimization process, different flow rates,
gradient elution programs with different run times were trialed which will be discussed

later in the section 4.3.

4.2.3.2. Mass spectrometry
Mass spectrometric detection of peptides was carried out in positive electrospray

ionization mode by utilizing Q3 scan feature of triple quadrupole for better sensitivity than
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Q1 scan. The mass range was set between m/Z 500-1250 at a scan rate of 200Da/s. The
source dependent parameters for positive mode were as follows: curtain gas at 35 psi;

collision assisted dissociation gas at high; ion spray voltage at 5000 V; source temperature
at 450°C; sheath gas at 30 psi and desolvation gas at 30 psi. The compound dependent

parameters were as follows: declustering potential at 110 V; entrance potential at 15 V and

collision cell exit potential 23 V. For negative mode the parameters were changed to ion
spray voltage at -4500 V, declustering potential at -110 V; entrance potential at -15 V and

collision cell exit potential -23 V.

4.2.4 Data interpretation

The MS scan data acquired on the Analyst software of AB Sciex triple quadrupole

mass spectrometer was further processed in Skyline software [74]. Deconvolution of mass

spectra was performed manually and in Skyline to confirm the identity of peptides. Data
processing in Skyline was performed by first inputting the amino acid sequence of PTB in

the form of a FASTA file from UniProt database and digesting in silico with Asp-N [75].

Peptide settings for detecting target peptide were as follows: missed cleavages at 0; length
of peptide at 2-60; amino acid modifications at carbamidomethylation for cysteine (fixed)
and carboxylation for glutamic acid residues (variable). Transition settings for all the

peptides were as follows: precursor and product ion masses at average mass; precursor and
ion charges at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11; ion match tolerance at 0.5 m/Z and scan range

at 500 - 1250 m/Z. A separate data processing was done for the rest of the peptides with

the same settings as above but, without gamma carboxy modification for Glus.
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4.3 Results and Discussion
Because middle-down approach is newly emerging and Asp-N is not as well studied as

Trypsin, literature on utility of Asp-N for LC-MS applications is limited. [30, 31]. Our
aim was therefore to develop conditions for digesting PTB with Asp-N optimized to

produce the greatest sequence coverage, which was conducted in the formation of 7
protocols varying the digestion conditions. The general workflow for digestion of PTB is

depicted in the fig. 4.5. PTB was first denatured in 8M urea to break down the quaternary
structure of the protein to produce a polypeptide chain. We have also investigated if 6M

Guanidine Hydrochloride provides a better sequence coverage than urea in protocol 4 as
Guanidine Hydrochloride is regarded as a stronger denaturing agent than urea. Denatured
PTB was then reduced in 9.9 mM DTT (except in protocol 1 where 4.3 mM DTT was used)
to disrupt disulfide bonds between cysteine residues which were alkylated using 30.2 mM

IAA (except in protocol 1 where 36 mM IAA was used) to prevent re-formation of disulfide
bonds. The concentration of denaturing agent was reduced to < 2M (except in protocol 5

where the concentration of urea after dilution was 2.8M) by addition of sufficient volume
of 100 mM ABC buffer to prevent denaturation of Asp-N. Addition of ABC buffer also

maintains a pH of 7-8 optimal for activity of Asp-N. Asp-N was added at an enzyme to

protein ratio of 1:10 (except in protocol 1 where the ratio is 1:20) and incubated at 37°C.

PTB was digested for variable times including 6 hours, 3.5 hours, 1 hour and 30 min after
which Asp-N activity was inactivated by reducing the pH to 2 with formic acid or TFA.

The sample was desalted to remove undesirable matrix components, and peptides were
concentrated using C18 ZipTips or spin filters (MWCO 3K) before injection into the LC-
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PTB standard
__________________ ,

Denaturation
._________________________________________________________ /

Reduction

Alkylation

Digestion with
Asp-N

Desalting

LC-MS analysis

Deconvolution of
MS spectra

Figure 4. 5 General plan followed for protocols 1-7
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MS. However, in protocols 3, 4 and 10, sample was cleaned prior to digestion in order to

reduce concentration of urea and increase the concentration of PTB.

4.3.1 Protocol 1
Because Asp-N is not a widely used protease for enzymatic digestion in proteomics, there
is limited literature available which describe the conditions for optimal digestion. Hence,

we performed denaturation, reduction, alkylation and digestion based on a previously

studied Trypsin based method (in our laboratory) and according to the manufacturer’s
protocol as follows: 5 ug of PTB was denatured with 50 uL of 8M urea in 100mM ABC

buffer and vortexing on low speed for 40 min. It was then reduced with DTT to a final

concentration of 4.3 mM by vortexing on low speed for 30 min. Alkylation was performed
using IAA to a final concentration of 36 mM and incubated in the dark for 30 min. In order

to prevent the denaturation of Asp-N, the concentration of urea was reduced to 1.8 M by

the addition of ABC. Asp-N was added at enzyme: protein ratioof 1:20 at pH 7.0 and
incubated for 6 hours at 37 °C. After 6 hours, digestion was stopped by inactivating the

enzyme by lowering the pH to 2 with TFA. The peptides were desalted and enriched by
solid phase extraction carried out using C18 ZipTips as follows: the C18 sorbent in the
ZipTip was activated using acetonitrile and 0.1 % formic acid after which the digest was

loaded. The sorbent was then washed with 0.1% formic acid and the peptides were eluted

into 10 uf of 60% acetonitrile. The final volume was made upto 50 uf with 0.1% formic
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A

B
ANTFLEEVRKGNLERECVEETCSYEEAFEALESSTAT|DVFWAKYTACETARTPR|DKLAACLEG
NCAEGLGTNYRGHVNITRSGIECQLWRSRYPHKPEINSTTHPGA |DLQENFCRNP|DSSTTGPWC
YTT|DPTVRRQECSIPVCGQ|DQVTVAMTPRSEGSSVNLSPPLEQCVP|DRGQQYQGRLAVTTHG
LPCLAWASAQAKALSKHQ|DFNSAVQLVENFCRNP|DG|DEEGVWCYVAGKPG|DFGYC|DLNYC
EEAVEEETG|DGL|DE|DS|DRAIEGRTATSEYQTFFNPRTFGSGEA|DCGLRPLFEKKSLE|DK
TERELLESYI|DGRIVEGS|DAEIGMSPWQVMLFRKSPQELLCGASLIS|DRWVLTAAHCLLYPP
W|DKNFTEN|DLLVRIGKHSRTRYERNIEKISMLEKIYIHPRYNWRENL |DR|DIALMKLKKPVA
FS|DYIHPVCLP|DRETAASLLQAGYKGRVTGWGNLKETWTANVGKGQPSVLQVVNLPIVERPVC
K|DSTRIRIT|DNMFCAGYKP|DEGKRG|DACEG|DSGGPFVMKSPFNNRWYQMGIVSWGEGC|D
R|DGKYGFYTHVFRLKKWIQKVI|DQFGE

Figure 4. 6 A) Total ion chromatogram (full scan) of Asp-N digest of standard PTB using
protocol 1 B) 0% Sequence coverage (detected peptides in bold)
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acid. 10 uL of the sample was injected into LC-MS at a flow at rate of 50 uL/min and 65

min gradient elution. The elution program was as follows: 0% B (initial), 0-90% B (55
min), 90% B (5 min), 90-0% B (3 min) and 0% B (2 min). Fig. 4.6 A shows the total ion

chromatogram of the Asp-N digest of PTB obtained in full scan mode. Though a few peaks
were observed in the chromatogram, no peptides were identified in the entire

chromatogram resulting in 0% sequence coverage as shown in figs. 4.6 B and 4.7 implying
that digestion probably did not take place at all. There could be several reasons for
inadequate digestion, such as low starting concentration of protein, inaccessibility of

cleavage sites by Asp-N due to 4.5 mM of DTT being inadequate for reduction, or over
alkylation by IAA (at undesirable places like lysine, aspartic acid and glutamic acid
residues) [35]. Another possibility is that the digestion time was too long which might have
led to degradation of peptides generated [36]. Another possibility is that native Asp-N is
not functional and suitable for digesting PTB.

4.3.2 Protocol 2
Recombinant Asp-N was found to have more efficiency and sequence coverage than native

Asp-N as reported by the same manufacturer and hence was chosen for use in protocol 2

[32]. Further, the amount of protein was doubled to 10 ug to improve chances of detecting
the peptides as well as digestion efficiency. The concentration of DTT was increased to 9.9
mM and the ratio of IAA to DTT was maintained at approximately 3:1 to ensure adequate
reduction and alkylation. The enzyme: protein ratio was also increased to 1: 10 from 1:20
to make more Asp-N available for digestion and digestion time was reduced to 3.5 hours
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from 6 hours. The modified procedure was carried out as follows: 10 ug of PTB was
denatured with 90 uL of 8M urea in 100mM ABC buffer and incubated at 37 °C for 15
min. It was then reduced with DTT to a final concentration of 9.9 mM by incubating at 37

°C for 30 min. Alkylation was performed using IAA to a final concentration of 30.2 mM
and incubated in the dark for 30 min. In order to prevent the denaturation of Asp-N, the

concentration of urea was reduced to 2.8 M by the addition of ABC. Asp-N was added at
enzyme: protein ratio of 1:10 at pH 7.5 and incubated for 3.5 hours at 37 °C. After 3.5
hours, digestion was stopped by inactivating the enzyme by lowering the pH to 2 with TFA.

The peptides were desalted and enriched by solid phase extraction carried out using C18

ZipTips as follows. The C18 sorbent in the ZipTip was activated using acetonitrile and 0.1
% formic acid after which the digest was loaded. The sorbent was then washed with 0.1%
formic acid and the peptides were eluted into 10 uL of 60% acetonitrile. The final volume
was made up to 50 uL with 0.1% formic acid. 10 ul of the sample was injected into LC-

MS at a flow at rate of 50 uL/min and run time of 95 min. The elution program was

extended to 95 min to facilitate better chromatographic resolution of peptides as follows:
0% B (initial), 0-90% B (80 min), 90% B (5 min), 90-0% B (5 min) and 0% B (5 min). Fig.

4.8 A shows the total ion chromatogram of the Asp-N digest of PTB obtained in full scan

mode using protocol 2. Nine out of thirty peptides were detected with a sequence coverage
of 33.7% as shown in fig. 4.8 B and 4.9 thus showing that new conditions are favorable for

digestion but need to be improved further.
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Figure 4. 8 A) Total ion chromatogram (full scan) of Asp-N digest of standard PTB using
protocol 2 B) 33.7 % Sequence coverage (detected peptides in bold)
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4.3.3 Protocol 3
In protocol 3, size exclusion spin filters were used not only to remove urea and other

chemicals added before digestion but also to concentrate PTB in the sample before
digesting it with Asp-N. In the modified procedure 10 ug of PTB was denatured with 90
uL of 8M urea in 100mM ABC buffer and incubated at 37 °C for 15 min. It was then
reduced with DTT to a final concentration of 9.9 mM and incubated at 37 °C for 30 min.

Alkylation was performed using IAA to a final concentration of 30.2 mM and incubated in
the dark for 30 min. The sample was then cleaned up using Amicon 0.5 mL spin filters
(MWCO 3K). For this, a spin filter was placed in a microcentrifuge tube, activated by

centrifuging with 200 uL water at 14000 rpm for 6 min. Sample was loaded, the filter was

spun at 14000 rpm for 10 min and washed by spinning at 14000rpm with 200 uL of ABC
buffer for another 10 min. The sample (approximately 130 uL) remaining in the spin filter
was collected by inverting the filter into another microcentrifuge tube and spinning at 1000

rpm for 2 min. After clean-up, Asp-N was added at enzyme: protein ratio of 1:10 at pH 7.5
and incubated for 3.5 hours at 37 °C. After 3.5 hours, digestion was stopped by inactivating

the enzyme by lowering the pH to 2 with formic acid. 30 uL of sample was injected into
LC- MS at a flow at rate of 50 uL/min and run time of 95 min using the same elution

program as above. The injection volume was increased to 30 uL as final sample volume
was increased approximately three-fold. We have also investigated if digestion was better

with guanidine hydrochloride as it was considered as a stronger denaturing agent than urea.

For this, another sample was denatured with 6M guanidine hydrochloride and treated and

analyzed as described above. The urea treated sample yielded 23 of 30 peptides with a
sequence coverage of 46.1 % (fig. 4.10 A and B) while 6M guanidine hydrochloride treated
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Figure 4. 10 A) Total ion chromatogram (full scan) of Asp-N digest of standard PTB
using protocol with urea as denaturing agent 3 B) 46.1 % Sequence coverage (detected
peptides in bold)
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Figure 4. 12 A) Total ion chromatogram (full scan) of Asp-N digest of standard PTB
using protocol 3 with guanidine hydrochloride as denaturing agent B) 40.1 % Sequence
coverage (detected peptides in bold)
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sample yielded 11 of 30 peptides with a sequence coverage of 40.1% (fig. 4.12 A and B)
suggesting that urea was a better denaturing agent than guanidine hydrochloride. The

overall intensity of peptides in both the cases was higher than those of protocol 2 as
observed in figs. 4.11 and 4.13.

4.3.4 Protocol 4
In protocol 4, we have investigated if extraction of peptides with spin filters after

digestion resulted in a shift in the sequence coverage towards peptides with higher

molecular weight, by removing components of molecular weight less than 3 kDa. This was
conducted as follows: 10 ug of PTB was denatured with 90 uL of 8M urea in 100mM ABC
buffer and incubated at 37 °C for 15 min. It was then reduced with DTT to a final

concentration of 9.9 mM by incubated at 37 °C for 30 min. Alkylation was performed using
IAA to a final concentration of 30.2 mM and incubated in the dark for 30 min. In order to

prevent denaturation of Asp-N, concentration of urea was reduced to 2.8M by the addition
of ABC buffer. Asp-N was added at an enzyme to protein ratio of 1:10 at pH 7.5 and
incubated for 3.5 hours at 37 °C. After 3.5 hours, digestion was stopped by inactivating the

enzyme by lowering the pH to 2 with TFA. The sample was then cleaned up using Amicon

0.5 mL centrifugal filters (MWCO 3K). For this, a spin filter was placed in a
microcentrifuge tube and activated by centrifuging with 200 uL water at 14000 rpm for 6
min. Sample was loaded and spun at 14000 rpm for 10 min and washed with 50 uL of water

for another 10 min at 14000 rpm. The concentrate remaining in the spin filter was collected
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Figure 4. 14 A) Total ion chromatogram (full scan) of Asp-N digest of standard PTB
using protocol 4 B) 73.3% Sequence coverage (detected peptides in bold)

121

intensity, (x 1000000) cps

ANTF LEEVRKGN LERECVEETCSYE EAFEALESSTAT
DVFWAKYTACETARTPR
D KLAACLEGNCAEGLGTNYRG HVNITRSGIECQLWRSRYPHKPEINSTTH PGA

DLQENFCRNP

DSSTTGPWCYTT
DPTVRRQECSIPVCGQ
D QVTVAM TP RS E GSSV NLSP P LE QCVP
DRGQQYQGRLAVTTHGLPCLAWASAQAKALSKHQ
DFNSAVQLVENFCRNP

DG
DEEGVWCYVAGKPG
DFGYC
DLN YŒEAVEEETG

DGL
DE

DS
DRA IEGRTATSEYQ.TFFNPRTFGSGEA

122

DCGLRPLFEKKSLE

DKTERELLESYI
DGRIVEGS
DAEIGMSPWQVMLFRKSPQELLCGAS US

D RWVLTAAHCLLYPPW
D KN FT EN
D LLVRIGKHSRTRYERNIE KISM LEKI YIHPRYNWRENL

DR
DIALMKLKKPVAFS
DYIHPVCLP

D RE TAA S LLQA GY KG RVTG WG N LK ET WTAN VG K GQPS VLQVVN LP IVER P VCK
D STR IR IT

DNMFCAGYKP
DEG KRG
DACEG
DSGGPFVMKSPFNN RWYQMGIVSWG EGC

DR
D GKYG FYTHV FRLK K WIQKVI

DQFGE

by inverting the filter into another microcentrifuge tube and spinning at 1000 rpm for 2
min. 30 uL of the sample was injected into LC-MS at a flow at rate of 50 uL/min using the

same elution program as above. From fig. 4.14 A and B, it can be observed that the
sequence coverage of 73.3% was higher than the previous protocol with 20 of 30 peptides
(both low molecular weight and higher molecular weight) being detected. The overall

intensity of the peptides was also higher than the previous protocol suggesting that using
spin filters post digestion was more advantageous than using them before digestion.

4.3.5 Protocol 5
Bovine serum albumin (BSA) was found to improve digestion by possibly stabilizing the

enzyme and by reducing adsorptive losses during digestion [37]. In order to study if BSA

could improve sequence coverage of PTB, 5ug of BSA was spiked in the sample just before
digestion with Asp-N. The digestion was conducted as follows: I0ug of PTB was denatured
with 90 uL of 8M urea in 100mM ABC buffer and incubated at 37 °C for 15 min. It was

then reduced with DTT to a final concentration of 9.9 mM by incubated at 37 °C for 30
min. Alkylation was performed using IAA to a final concentration of 30.2 mM and

incubated in the dark for 30 min. 5 uL of 1mg/mL. In order to prevent the denaturation of

Asp-N, the concentration of urea was reduced to 2.8 M by the addition of ABC buffer.
BSA was added into the sample just before Asp-N was added at an enzyme to protein ratio

of 1:10 at pH 7.5 and incubated for 3.5 hours at 37 °C. After 3.5 hours, digestion was
stopped by inactivating the enzyme by lowering the pH to 2 with TFA. The sample was

then cleaned up using Amicon
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Figure 4. 16 A) Total ion chromatogram (full scan) of Asp-N digest of standard PTB
using protocol 5 B) 67.8% Sequence coverage (detected peptides in bold)
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0.5 mL centrifugal filters (MWCO 3K). For this, a spin filter was placed in a
microcentrifuge tube and was activated by centrifuging with 200 uL water at 14000 rpm
for 6 min. Sample was then loaded and spun at 14000 rpm for 10 min and washed with 50

uL of water for another 10 min at 14000 rpm. The concentrate remaining in the spin filter
was collected by inverting the filter into another microcentrifuge tube and spinning at 1000

rpm for 2 min. 30 uL of the sample was injected into LC-MS at a flow at rate of 50 uL/min
with a run time of 95 min using the same elution program as above. From fig. 4.16 A and

B, it can be observed that spiking BSA before digestion reduced the sequence coverage to

67.8 % with 18 of 30 peptides detected but increased the intensity of most peptides that
were detected. Hence, addition of BSA might not be beneficial for improving sequence
coverage.

4.3.6 Protocol 6
We have also studied if the recovery of peptides decreased due to adsorptive losses from
the use of ZipTips and spin filters due to adsorptive losses. In order to evaluate whether or
not this was the case, digestion was stopped using formic acid instead of TFA (to avoid ion

suppression) and the sample was directly injected into LC-MS without desalting or peptide

enrichment. The digestion was conducted as follows: 10 ug of PTB was denatured with 90
uL of 8M urea in 100mM ABC buffer and incubating at 37 °C for 15 min. It was then
reduced with DTT to a final concentration of 9.9 mM by incubating at 37 °C for 30 min.

Alkylation was performed using IAA to a final concentration of 30.2 mM and incubated in
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Figure 4. 18 A) Total ion chromatogram (full scan) of Asp-N digest of standard PTB
using protocol 6 B) 65% Sequence coverage (detected peptides in bold)
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the dark for 30 min. In order to prevent the denaturation of Asp-N, the concentration of

urea was reduced to 2.8M by the addition of ABC buffer. Asp-N was added at an enzyme
to protein ratio of 1:10 at pH 7.5 and incubated for 3.5 hours at 37 °C. After 3.5 hours,
digestion was stopped by inactivating the enzyme by lowering the pH to 2 with formic
acid. 30 uL of the sample was injected into LC-MS at a flow at rate of 50 uL/min and run
time of 95 min using the same elution program as above. As can be seen in fig. 4.18 A and

B, sequence coverage decreased to 65% with 17 of 30 peptides detected. The overall
intensities of the detected peptides were also lower which suggests that peptide enrichment

using spin filters was necessary.

4.3.7 Protocol 7

Specificity of Asp-N was found to be high at shorter digestion times with decreased number
of cleavages at Glus. Therefore, we decreased the digestion time to one hour to determine
if better sequence coverage could be attained. Additionally, spin filters were used to

achieve buffer exchange and concentrate the sample prior to digestion with Asp-N with
longer centrifugation times. The digestion was conducted as follows: 10 ug of PTB was

denatured with 90 uL of 8M urea in 100mM ABC and incubated at 37 °C for 15 min. It
was then reduced with DTT to a final concentration of 9.9 mM by incubating at 37 °C for
30 min. Alkylation was performed using IAA to a final concentration of 30.2 mM and

incubated in the dark for 30 min. The sample was then cleaned up using Amicon 0.5 mL
centrifugal filters (MWCO 3K). For this, a spin filter was placed in a microcentrifuge tube
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FS|DYIHPVCLP|DRETAASLLQAGYKGRVTGWGNLKETWTANVGKGQPSVLQVVNLPIVERPVC
K|DSTRIRIT|DNMFCAGYKP|DEGKRG|DACEG|DSGGPFVMKSPFNNRWYQMGIVSWGEGC|D
R|DGKYGFYTHVFRLKKWIQKVI|DQFGE

Figure 4. 20 A) Total ion chromatogram (full scan) of Asp-N digest of standard PTB using
protocol 7 B) 77.9 % Sequence coverage (detected peptides in bold)
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intensity, (x 1000000) cps

ANTFLEEVRKGNLERECVEETCSYEEAFEALESSTAT
DVFWAKYTACETARTPR
DKLAACLEGNCAEGLGTNYRGHVNITRSGIECQLWRSRYPHKPEINSTTHPGA

DLQENFCRNP

DSSTTGPWCYTT
DPTVRRQECSIPVCGQ

DQVTVAMTPRSEGSSVNLSPPLEQCVP

D RG QQYQGRLAVTTH GL PC LAW ASA QAKALSKHQ

DFNSAVQLVEN FCRN P
DG
DEEGVWCYVAGKPG

DFGYC
D LNYCEEAVEEETG

DGL
DE

DS
D RA IEG RTATSEYQTFFN PRTFGSG EA
DCGLRPLFEKKSLE
DKTERELLESYI

DGRIVEGS
DAEIGMSPWQVMLFRKSPQELLCGAS LIS

DRWVLTAAHCLLYPPW
DKNFTEN

D LLVRIG K HSRT RYERN IE Kl SM LE Kl YIH PRYN WREN L

DR
DIALMKLKKPVAFS
DYIHPVCLP

D RETAASLLQA GY KG RVTGWG N LK ET WTANVG KGQPSVLQWN LP IVERPVCK

DSTRIRIT

DNMFCAGYKP
DEGKRG
DACEG
D SGG P FVM KSPFN N RWYQM GIVSWG EG C

DR
DGKYGFYTHVFRLKKWIQKVI
DQFGE

was activated by centrifuging with 200 uL water at 14000 rpm for 6 min. Sample was

loaded and spun at 14000 rpm for 15 min and washed with 360 uL of ABC for another 15

min at same speed. The sample (approximately 50 uL) remaining in the spin filter was
collected by inverting the filter into another microcentrifuge tube and spinning at 1500 rpm
for 2 min. After clean-up, Asp-N was added at enzyme: protein ratio of 1:10 at pH 7.5 and

incubated for 3.5 hours at 37 °C. After 3.5 hours, digestion was stopped by inactivating the

enzyme by lowering the pH to 2 with formic acid. 30 uL of the sample was injected into

LC-MS at a flow at rate of 50 uL/min with and extended run time of 120 min. The gradient
elution program was also modified as follows: 0% B (initial), 0-90% B (105 min), 90% B
(5 min), 90-0% B (5 min) and 0% B (5 min).

As seen in fig 4.24 A and B, the sequence coverage was increased to 77.9% with
23 of 30 peptides detected which implies that digestion efficiency was improved even if

digestion time was reduced to one hour.

4.3.9 Peptide of interest
One of the common peptides that was not observed in all of the above experiments

was ANTFLEEVRKGNLERECVEETCSYEEAFEALESSTAT (peptide of interest)

which was essential to study the distribution of variants of DCP. Detection of peptide
DVFWAKYTACETARTPR in protocols 2, 4, 5, 6, 7 suggests Asp-N did cleave PTB at

Asp-38 to produce the desired peptide. There could be three possible reasons for the peptide
not being produced or detected. The first probable reason was that the presence of twenty

carboxyl residues in the peptide might be causing poor ionization in positive ionization
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mode and poor chromatographic behavior of the peptide in reverse phase HPLC. Second
possible reason could be the tendency of Asp-N to have promiscuity in its cleavage at Asp
as well as at Glu (which usually occurs at a rate 2000-fold lower and increases when

digestion times were longer). The third reason is the possibility of the formation of adducts

in positive mode. However, this was ruled out after data analysis did not reveal any sodium,

potassium or ammonium adducts. These are only speculations and the true reason as to
why the target peptide was not detected could only be confirmed by fine tuning the LCMS conditions using a synthetic peptide which contains the same sequence as that of the

desired peptide. Even though proteomics studies are predominantly carried out using
positive mode of ionization as Tryptic peptides with C-termial lysine and arginine residues

tend to ionize well in positive ionization mode, negative mode might be a potential

alternative in this case as it takes advantage of the 10-20 carboxyl groups available for de
protonation.

4.3.8 Digestion efficiency compared to Trypsin
In order to evaluate the digestion efficiency of Asp-N relative to most commonly used

protease, Trypsin, PTB was also digested with Trypsin. Digestion with Trypsin was carried
out as follows: 10 ug of PTB was denatured with 90 uL of 8M urea in 100mM ABC buffer

and incubated at 37 °C for 15 min. It was then reduced with DTT to a final concentration

of 9.9 mM by incubated at 37 °C for 30 min. Alkylation was performed using IAA to a

final concentration of 30.2 mM and incubated in the dark for 30 min. In order to prevent
the denaturation of Asp-N, the concentration of urea was reduced to 2.8 M by the addition
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of ABC buffer. Trypsin was added at enzyme: protein ratio of 1:10 at pH 7.5 and incubated
for 18 hours at 37 °C. After 18 hours, digestion was stopped by inactivating the enzyme by

lowering the pH to 2 with TFA. The peptides were desalted and enriched by solid phase
extraction carried out using C18 ZipTips as follows: the C18 sorbent in the ZipTip was
activated using acetonitrile and 0.1 % formic acid after which the digest was loaded. The

sorbent was then washed with 0.1% formic acid and the peptides were eluted into 10 uf of
60% acetonitrile. The final volume was made up to 50 u with 0.1% formic acid. 10 uL of

the sample was injected into LC-MS at a flow at rate of 50 uL/min and run time of 95 min.

The elution program was same as that in protocol 2. protocols 4 and 7 and lower than those
in protocol 6. As can be seen in fig. 4.22 A, it can be inferred that the sequence coverage
of Trypsin was 59.1% which was lower than that of Asp-N in protocols 4, 5, 6, 7. Fig 4.22

B suggests that overall intensities of tryptic peptides were comparable to those of Asp-N

peptides. These data suggest that Asp-N has better sequence coverage than Trypsin and
can be used for more effective digestion of PTB.

4.3.9 Digestion efficiency at low concentrations
Since the amount of DCP in patient samples would be present in nanogram amounts (which

could be further concentrated by immunoaffinity enrichment using MU-3 antibodies), we
evaluated the digestion efficiency at various initial amounts of PTB such as 10 ug, 5 ug, 1

ug, 0.1 ug and 0.05 ug using protocol 4. The sequence coverage decreased ten-fold from
10 to 0.05 ug as shown in table 4.2. However, we monitored the intensity of one of the
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A
ANTFLEEVR|K|GNLER|ECVEETCSYEEAFEALESSTATDVFWAK|YTACETAR| TPR|DK|LA
ACLEGNCAEGLGTNYR|GHVNITR|SGIECQLWR|SR|YPHKPEINSTTHPGADLQENFCR|NPD
SSTTGPWCYTTDPTVR|R|QECSIPVCGQDQVTVAMTPR|SEGSSVNLSPPLEQCVPDR|GQQYQ
GR|LAVTTHGLPCLAWASAQAK|ALSK|HQDFNSAVQLVENFCR|NPDGDEEGVWCYVAGKPGDF
GYCDLNYCEEAVEEETGDGLDEDSDR|AIEGR|TATSEYQTFFNPR|TFGSGEADCGLRPLFEK|
K|SLEDK|TER|ELLESYIDGR|IVEGSDAEIGMSPWQVMLFR|K|SPQELLCGASLISDR|WVL
TAAHCLLYPPWDK|NFTENDLLVR|IGK|HSR|TR|YER|NIEK|ISMLEK|IYIHPR|YNWR|E
NLDR|DIALMK|LK|KPVAFSDYIHPVCLPDR|ETAASLLQAGYK|GR|VTGWGNLK|ETWTANV
GK|GQPSVLQVVNLPIVERPVCKDSTR|IR|ITDNMFCAGYKPDEGK|R|GDACEGDSGGPFVMK
|SPFNNR|WYQMGIVSWGEGCDR|DGK|YGFYTHVFR|LK|K|WIQK|VIDQFGE

B

Figure 4. 22 A) 59.1% sequence coverage (detected peptides in bold) B) Intensities of
peptides detected in Tryptic digest of standard PTB
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Table 4. 2 Digestion efficiency at various initial concentrations of PTB

Initial
PTB
(ug)
10
5.0
1.0
0.1
0.05

amount of Amount injected
into LC-MS
(ug)
0.6
0.3
0.06
0.006
0.003

% sequence
coverage
73.3
58.0
37.1
22.4
7.80
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Intensity of peptide
DCGLRPLFEKKSLE
(106 cps)
20.1
15.3
3.40
0.40
0.13

peptides, detected in all five digests. The signal of the peptide DCGLRPLFEKKSLE was

1.3 x105 cps in the sample containing 0.05 ug of PTB (~ 3 ng injected into LC-MS).

4.4 Conclusion
A protocol for enzymatic digestion of PTB with Asp-N for LC-MS analysis has

been described to obtain a sequence coverage of 77.9%. With this protocol, LC-MS could
detect peptides when the initial amount digested was reduced to 0.05 ug. However, the

peptide of interest which is essential for identification of variants of DCP was not observed
most likely because of poor ionization or undesirable enzymatic cleavage at one or more
Glus. It would be worthwhile to fine tune LC-MS parameters using a synthetic peptide with

identical sequence and test the digest obtained from protocols 7 and 4. Additionally, the
duration of digestion and enzyme to protein ratio could be reduced further to suppress the

cleavages at Glus.
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CHAPTER V

CONCLUSIONS AND FUTURE DIRECTIONS
In this dissertation, LC-MS methods for qualitative and quantitative analyses of

various small and molecules that are clinically or pharmacologically relevant were
discussed. In chapter II, a high-throughput dilute-and-shoot flow injection MS/MS method
for quantification of GCA and UBL in human bile was described. This was the first mass

spectrometric method to simultaneously determine both the analytes in human bile. Simple
dilution without time consuming extraction steps, short run time of 2.5 min resulting in a
high throughput of 500 samples a day, and quantitation without HPLC separation render

the method suitable for routine clinical use. However, standard-addition used in the method
might not be ideal in a clinical setting, but it does eliminate the need of a blank bile matrix

that is difficult to obtain. In addition, our method is fast with a run time of only 2.5 min,

enabling high throughput analyses of over 500 samples a day. Though we have applied this

method to clinical samples and able to quantify the analytes in most of them, we do not
know if the samples belonged to healthy or diseased patients. We recommend the
application of the method to bile samples from normal and diseased patients which could

give us more information on utility of GCA and UBL as potential biomarkers for
Cholangiocarcinoma and Cholelithiasis respectively.
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In chapter III, an LC-MS/MS method for quantitative determination of TMZ in mouse

brain with a recovery of 82% and matrix effects within 15% has been developed and

validated for the first time. This was possible by using a two-step extraction process
involving a homogenization assisted by Proteinase K and protein precipitation with
ethanol. The method has been fully validated and applied to study samples. However, the

amount of TMZ detected in the study samples was below LLOQ because the samples were
collected long after the drug has probably been eliminated from the body. Hence, we
recommend that samples be collected within an hour of intra cerebral microdialysis and

quantified using our method. This will help estimate the amount of TMZ being
administered to the brain and assess the potential of using intra-cerebral microdialysis as

an alternative route of administration.
In chapter IV, a step wise optimization and development of a protocol for enzymatic

digestion of PTB with Asp-N for LC-MS analysis has been described. The protocol

developed provided a maximum sequence coverage of 77.9% which was higher than the

59.1% sequence coverage achieved by Trypsin. The method was able to detect peptides
when the amount of PTB digested was reduced to 0.05 ug. However, the peptide of interest

was not observed in any of the protocols probably because of poor ionization or enzymatic

cleavage of Glus over-digesting the peptide into smaller fragments. Though the sequence
coverage achieved was high, the method needs to be optimized further in order to confirm
if the peptide of interest could be produced by Asp-N. This could be achieved using a
synthetic peptide of identical sequence as that of DCP or PTB. First, the LC-MS parameters

could be optimized to ensure adequate ionization of the peptide so that it could be detected.
Then, the digest produced could be analyzed to check if the peptide could be identified. If
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the peptide could not be identified, a possible reason is the cleavage of the peptide of
interest at one or more Glus which could be suppressed by reducing the digestion time to

less than one hour or/and by decreasing the enzyme to protein ratio to less than 1:10.
Once the method is optimized to detect the peptide of interest, it could be applied to
study samples which are human serum belonging to HCC and Vitamin K deficient patients.
But, since concentration of DCP in human serum is much lower, it needs to be enriched to

be detected by LC-MS. This could be achieved by treating human serum samples with MU3 antibodies that selectively bind to DCP variants containing >6 Glus there by separating

them from other matrix components and DCP variants not relevant to diagnosis of HCC

followed by elution of DCP from the antigen antibody complex, denaturation, reduction,
alkylation, digestion using Asp-N and LC-MS analysis. This study could give insight into

the extent of degree in gamma carboxylation in HCC and vitamin K deficiency which in

turn would be beneficial to understand the mechanisms underlying both the disease

processes. If the distribution of DCP variants in both the cases varies, it will be possible to
distinguish Vitamin K deficiency from HCC without the need to undergo additional blood
work. Further, a quantification method for the corresponding DCP variants in serum could

be developed to predict the risk of HCC and to monitor the progression of HCC. If the
expected results are obtained, this method will be a better tool to diagnose HCC compared
to previous owing to its better specificity and its ability to diagnose HCC at an early stage.
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